


**CUMULATIVE
SUPPLEMENT 2
February 2024**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

44th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2024

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

44th EDITION

**Cumulative Supplement 2
February 2024**

CONTENTS

PAGE

Contents

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	viii
1.5	AVAILABILITY OF THE EDITION.....	ix
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xi
DRUG PRODUCT LISTS		
	Prescription Drug Product List.....	1-1
	OTC Drug Product List.....	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List.....	3-1
	Orphan Products Designations and Approvals List.....	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution.....	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM		
A.	Patent and Exclusivity Lists.....	A-1
B.	Patent and Exclusivity Terms.....	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

44th EDITION

**CUMULATIVE SUPPLEMENT 2
February 2024**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a

"@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOB/PRA) of any changes or corrections. The DOB/PRA can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
AKORN OPERATING CO LLC (AKORN)	EPIC PHARMA LLC (EPIC PHARMA LLC)
CADILA HEALTHCARE LTD (CADILA)	ZYDUS LIFESCIENCES LTD (ZYDUS LIFESCIENCES)
GLAXOSMITHKLINE (GLAXOSMITHKLINE)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)
GLAXOSMITHKLINE CONSUMER HEALTHCARE (GLAXOSMITHKLINE CONS)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)
GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS US LLC (GLAXOSMITHKLINE CONS)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)

LUPIN LTD
(LUPIN LTD)

CHARTWELL RX SCIENCES LLC
(CHARTWELL RX)

TARO PHARMACEUTICALS USA INC
(TARO)

TARO PHARMACEUTICALS INC
(TARO)

VERTICE PHARMA MANAGEMENT CORP
(VERTICE)

ENCUBE ETHICALS PRIVATE LTD
(ENCUBE)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

² Please consult the Active Section of the Orange Book for information on other strengths.

AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	-	RS

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u>	<u>DEC</u>	<u>MAR</u>	<u>JUN</u>	<u>SEP</u>	<u>DEC</u>
<u>COUNTED</u>	<u>2023</u>	<u>2024</u>	<u>2024</u>	<u>2024</u>	<u>2024</u>

DRUG PRODUCTS LISTED SINGLE SOURCE	23099 2784 (12.1%)
MULTISOURCE	20315 (87.9%)
THERAPEUTICALLY EQUIVALENT	20252 (87.7%)
NOT THERAPEUTICALLY EQUIVALENT	63 (0.3%)
EXCEPTIONS ⁴	46 (0.2%)
NEW MOLECULAR ENTITIES APPROVED	8
NUMBER OF APPLICANTS	1214

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

CAIN Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR Change. Dosage Form; Route of Administration

CFTG Change. A TE Code is added when a first time generic for an innovator is approved.

CMFD Change. The product is moved from the Discontinued Section due to a change in marketing status.

CMKT Change. RX to OTC marketing status switch.

CMS1 Change. Miscellaneous addition to list.

CMS2 Change. Miscellaneous deletion from list.

CPOT Change. Potency amount/unit.

CRLD Change. Reference Listed Drug

CHRS Change. Reference Standard

CTEC Change. Therapeutic Equivalence Code.

CTNA Change. Trade Name.

DISC Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL		ABACAVIR SULFATE AND LAMIVUDINE							
AB	!	CIPLA	EQ 600MG BASE;300MG	A091144	001	Mar 28, 2017	Jan	CHRS	
		EPZICOM							
	+	@ VIIV HLTHCARE	EQ 600MG BASE;300MG	N021652	001	Aug 02, 2004	Jan	DISC	
TABLET, FOR SUSPENSION;ORAL		ABACAVIR SULFATE AND LAMIVUDINE							
	+	@ MYLAN LABS LTD	EQ 60MG BASE;30MG	N204311	001	Dec 22, 2023	Jan	DISC	

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL		BUTALBITAL AND ACETAMINOPHEN							
AA		QUAGEN	300MG;50MG	A214305	001	Feb 01, 2024	Jan	NEWA	
AA			325MG;50MG	A214291	001	Jan 18, 2024	Jan	NEWA	

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE							
AA		QUAGEN	300MG;50MG;40MG	A214288	001	Feb 08, 2024	Jan	NEWA	
>D>	AA	RISE PHARMA	300MG;50MG;40MG	A214087	001	Aug 13, 2021	Feb	CAHN	
>D>	AA		325MG;50MG;40MG	A214087	002	Aug 13, 2021	Feb	CAHN	
>A>	AA	SENORES PHARMS	300MG;50MG;40MG	A214087	001	Aug 13, 2021	Feb	CAHN	
>A>	AA		325MG;50MG;40MG	A214087	002	Aug 13, 2021	Feb	CAHN	
TABLET;ORAL		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE							
AA		QUAGEN	325MG;50MG;40MG	A214287	001	Jan 18, 2024	Jan	NEWA	

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL		ACETAMINOPHEN AND CODEINE PHOSPHATE							
>D>	AA	AKORN	120MG/5ML;12MG/5ML	A040119	001	Apr 26, 1996	Feb	DISC	
>A>		@	120MG/5ML;12MG/5ML	A040119	001	Apr 26, 1996	Feb	DISC	
TABLET;ORAL		ACETAMINOPHEN AND CODEINE PHOSPHATE							
		@ SUN PHARM INDS LTD	300MG;30MG	A085868	001		Jan	DISC	

ACETAZOLAMIDE

TABLET;ORAL		ACETAZOLAMIDE							
>D>	AB	AJANTA PHARMA LTD	125MG	A211151	001	Sep 11, 2023	Feb	DISC	
>A>		@	125MG	A211151	001	Sep 11, 2023	Feb	DISC	
>D>	AB		250MG	A211151	002	Sep 11, 2023	Feb	DISC	
>A>		@	250MG	A211151	002	Sep 11, 2023	Feb	DISC	
		@ TORRENT	125MG	A213706	001	Jan 26, 2024	Jan	DISC	
AB			125MG	A213706	001	Jan 26, 2024	Jan	NEWA	
		@	250MG	A213706	002	Jan 26, 2024	Jan	DISC	
AB			250MG	A213706	002	Jan 26, 2024	Jan	NEWA	

ACETYLCYSTEINE

SOLUTION;INHALATION, ORAL		ACETYLCYSTEINE							
>D>	AN	EXELA PHARMA	20%	A205643	001	Nov 01, 2023	Feb	DISC	
>A>		@	20%	A205643	001	Nov 01, 2023	Feb	DISC	

ACETYLCYSTEINE LYSINE

FOR SOLUTION;ORAL		LEGUBETI							
>A>		+	GALEPHAR	EQ 500MG BASE/PACKET	N215040	001	Feb 13, 2024	Feb	NEWA
>A>		+	!	EQ 2.5GM BASE/PACKET	N215040	002	Feb 13, 2024	Feb	NEWA

ADENOSINE

SOLUTION;INTRAVENOUS		ADENOSINE							
>D>	AP	HOSPIRA	60MG/20ML (3MG/ML)	A203883	001	Mar 24, 2014	Feb	DISC	
>A>		@	60MG/20ML (3MG/ML)	A203883	001	Mar 24, 2014	Feb	DISC	
>D>	AP		90MG/30ML (3MG/ML)	A203883	002	Mar 24, 2014	Feb	DISC	
>A>		@	90MG/30ML (3MG/ML)	A203883	002	Mar 24, 2014	Feb	DISC	

ALBUTEROL SULFATE; BUDESONIDE

AEROSOL, METERED; INHALATION
AIRSUPRA

+! ASTRAZENECA EQ 0.09MG BASE/INH;0.08MG/INH N214070 001 Jan 10, 2023 Jan CPOT

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL
AMANTADINE HYDROCHLORIDE

@ GENUS 50MG/5ML A076352 001 Sep 10, 2004 Jan CAHN

AMCINONIDE

LOTION; TOPICAL
AMCINONIDE

! GENUS 0.1% A076329 001 Nov 06, 2002 Jan CAHN

OINTMENT; TOPICAL
AMCINONIDE

AB ! GENUS 0.1% A076096 001 Nov 19, 2002 Jan CAHN

AMLODIPINE BESYLATE

TABLET; ORAL
AMLODIPINE BESYLATE

>A> @ AIPING PHARM INC EQ 2.5MG BASE A077759 001 Jul 09, 2007 Feb CAHN
>A> @ EQ 5MG BASE A077759 002 Jul 09, 2007 Feb CAHN
>A> @ EQ 10MG BASE A077759 003 Jul 09, 2007 Feb CAHN
@ SUN PHARM INDS LTD EQ 2.5MG BASE A077974 001 Jul 09, 2007 Jan DISC
@ EQ 5MG BASE A077974 002 Jul 09, 2007 Jan DISC
@ EQ 10MG BASE A077974 003 Jul 09, 2007 Jan DISC
>D> @ UPSHER SMITH LABS EQ 2.5MG BASE A077759 001 Jul 09, 2007 Feb CAHN
>D> @ EQ 5MG BASE A077759 002 Jul 09, 2007 Feb CAHN
>D> @ EQ 10MG BASE A077759 003 Jul 09, 2007 Feb CAHN

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL
AMLODIPINE AND OLMESARTAN MEDOXOMIL

>D> @ SCIEGEN PHARMS INC EQ 5MG BASE;20MG A209010 001 Dec 03, 2018 Feb CMFD
>A> AB EQ 5MG BASE;20MG A209010 001 Dec 03, 2018 Feb CMFD
>D> @ EQ 5MG BASE;40MG A209010 002 Dec 03, 2018 Feb CMFD
>A> AB EQ 5MG BASE;40MG A209010 002 Dec 03, 2018 Feb CMFD
>D> @ EQ 10MG BASE;20MG A209010 003 Dec 03, 2018 Feb CMFD
>A> AB EQ 10MG BASE;20MG A209010 003 Dec 03, 2018 Feb CMFD
>D> @ EQ 10MG BASE;40MG A209010 004 Dec 03, 2018 Feb CMFD
>A> AB EQ 10MG BASE;40MG A209010 004 Dec 03, 2018 Feb CMFD

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL
ADDERALL XR 10

AB1 + TAKEDA PHARMS USA 2.5MG;2.5MG;2.5MG;2.5MG N021303 001 Oct 11, 2001 Jan CTEC
ADDERALL XR 15
AB1 + TAKEDA PHARMS USA 3.75MG;3.75MG;3.75MG;3.75MG N021303 006 May 22, 2002 Jan CTEC
ADDERALL XR 20
AB1 + TAKEDA PHARMS USA 5MG;5MG;5MG;5MG N021303 002 Oct 11, 2001 Jan CTEC
ADDERALL XR 25
AB1 + TAKEDA PHARMS USA 6.25MG;6.25MG;6.25MG;6.25MG N021303 004 May 22, 2002 Jan CTEC
ADDERALL XR 30
AB1 +! TAKEDA PHARMS USA 7.5MG;7.5MG;7.5MG;7.5MG N021303 003 Oct 11, 2001 Jan CTEC
ADDERALL XR 5
AB1 + TAKEDA PHARMS USA 1.25MG;1.25MG;1.25MG;1.25MG N021303 005 May 22, 2002 Jan CTEC
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE
AB1 ACTAVIS ELIZABETH 1.25MG;1.25MG;1.25MG;1.25MG A077302 001 Jun 22, 2012 Jan CTEC
AB1 2.5MG;2.5MG;2.5MG;2.5MG A077302 002 Jun 22, 2012 Jan CTEC
AB1 3.75MG;3.75MG;3.75MG;3.75MG A077302 003 Jun 22, 2012 Jan CTEC
AB1 5MG;5MG;5MG;5MG A077302 004 Jun 22, 2012 Jan CTEC
AB1 6.25MG;6.25MG;6.25MG;6.25MG A077302 005 Jun 22, 2012 Jan CTEC
AB1 7.5MG;7.5MG;7.5MG;7.5MG A077302 006 Jun 22, 2012 Jan CTEC
AB1 ANI PHARMS 1.25MG;1.25MG;1.25MG;1.25MG A205401 001 Jan 22, 2019 Jan CTEC
AB1 2.5MG;2.5MG;2.5MG;2.5MG A205401 002 Jan 22, 2019 Jan CTEC
AB1 3.75MG;3.75MG;3.75MG;3.75MG A205401 003 Jan 22, 2019 Jan CTEC
AB1 5MG;5MG;5MG;5MG A205401 004 Jan 22, 2019 Jan CTEC
AB1 6.25MG;6.25MG;6.25MG;6.25MG A205401 005 Jan 22, 2019 Jan CTEC
AB1 7.5MG;7.5MG;7.5MG;7.5MG A205401 006 Jan 22, 2019 Jan CTEC
AB1 ASCENT PHARMS INC 1.25MG;1.25MG;1.25MG;1.25MG A214959 001 Sep 29, 2021 Jan CTEC

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A214959	002	Sep 29, 2021	Jan CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A214959	003	Sep 29, 2021	Jan CTEC
AB1		5MG; 5MG; 5MG; 5MG	A214959	004	Sep 29, 2021	Jan CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A214959	005	Sep 29, 2021	Jan CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A214959	006	Sep 29, 2021	Jan CTEC
AB1	ELITE LABS INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A212037	001	Dec 11, 2019	Jan CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A212037	002	Dec 11, 2019	Jan CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A212037	003	Dec 11, 2019	Jan CTEC
AB1		5MG; 5MG; 5MG; 5MG	A212037	004	Dec 11, 2019	Jan CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A212037	005	Dec 11, 2019	Jan CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A212037	006	Dec 11, 2019	Jan CTEC
AB1	GRANULES	1.25MG; 1.25MG; 1.25MG; 1.25MG	A217027	001	Jan 23, 2023	Jan CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A217027	002	Jan 23, 2023	Jan CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A217027	003	Jan 23, 2023	Jan CTEC
AB1		5MG; 5MG; 5MG; 5MG	A217027	004	Jan 23, 2023	Jan CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A217027	005	Jan 23, 2023	Jan CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A217027	006	Jan 23, 2023	Jan CTEC
AB1	IMPAX LABS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A076852	001	Feb 16, 2016	Jan CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A076852	002	Feb 16, 2016	Jan CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A076852	003	Feb 16, 2016	Jan CTEC
AB1		5MG; 5MG; 5MG; 5MG	A076852	004	Feb 16, 2016	Jan CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A076852	005	Feb 16, 2016	Jan CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A076852	006	Feb 16, 2016	Jan CTEC
AB1	LANNETT CO INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A214403	001	Nov 26, 2021	Jan CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A214403	002	Nov 26, 2021	Jan CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A214403	003	Nov 26, 2021	Jan CTEC
AB1		5MG; 5MG; 5MG; 5MG	A214403	004	Nov 26, 2021	Jan CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A214403	005	Nov 26, 2021	Jan CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A214403	006	Nov 26, 2021	Jan CTEC
AB1	RHODES PHARMS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A210651	001	May 17, 2019	Jan CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A210651	002	May 17, 2019	Jan CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A210651	003	May 17, 2019	Jan CTEC
AB1		5MG; 5MG; 5MG; 5MG	A210651	004	May 17, 2019	Jan CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A210651	005	May 17, 2019	Jan CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A210651	006	May 17, 2019	Jan CTEC
AB1	SPECGX LLC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A211547	001	Apr 22, 2019	Jan CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A211547	002	Apr 22, 2019	Jan CTEC
AB2		3.125MG; 3.125MG; 3.125MG; 3.125MG	A211546	001	Aug 31, 2023	Jan CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A211547	003	Apr 22, 2019	Jan CTEC
AB1		5MG; 5MG; 5MG; 5MG	A211547	004	Apr 22, 2019	Jan CTEC
AB2		6.25MG; 6.25MG; 6.25MG; 6.25MG	A211546	002	Aug 31, 2023	Jan CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A211547	005	Apr 22, 2019	Jan CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A211547	006	Apr 22, 2019	Jan CTEC
AB2		9.375MG; 9.375MG; 9.375MG; 9.375MG	A211546	003	Aug 31, 2023	Jan CTEC
AB2		12.5MG; 12.5MG; 12.5MG; 12.5MG	A211546	004	Aug 31, 2023	Jan CTEC
AB2	SUN PHARM INDS INC	3.125MG; 3.125MG; 3.125MG; 3.125MG	A215997	001	Sep 27, 2023	Jan CTEC
AB2		6.25MG; 6.25MG; 6.25MG; 6.25MG	A215997	002	Sep 27, 2023	Jan CTEC
AB2		9.375MG; 9.375MG; 9.375MG; 9.375MG	A215997	003	Sep 27, 2023	Jan CTEC
AB2		12.5MG; 12.5MG; 12.5MG; 12.5MG	A215997	004	Sep 27, 2023	Jan CTEC
AB1	SUN PHARM INDUSTRIES	1.25MG; 1.25MG; 1.25MG; 1.25MG	A211715	001	May 17, 2019	Jan CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A211715	002	May 17, 2019	Jan CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A211715	003	May 17, 2019	Jan CTEC
AB1		5MG; 5MG; 5MG; 5MG	A211715	004	May 17, 2019	Jan CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A211715	005	May 17, 2019	Jan CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A211715	006	May 17, 2019	Jan CTEC
AB2	TEVA PHARMS USA	3.125MG; 3.125MG; 3.125MG; 3.125MG	A210876	001	Jan 31, 2022	Jan CTEC
AB2		6.25MG; 6.25MG; 6.25MG; 6.25MG	A210876	002	Jan 31, 2022	Jan CTEC
AB2		9.375MG; 9.375MG; 9.375MG; 9.375MG	A210876	003	Jan 31, 2022	Jan CTEC
AB2		12.5MG; 12.5MG; 12.5MG; 12.5MG	A210876	004	Jan 31, 2022	Jan CTEC
	MYDAYIS					
AB2	+ TAKEDA PHARMS USA	3.125MG; 3.125MG; 3.125MG; 3.125MG	N022063	001	Jun 20, 2017	Jan CTEC
AB2	+	6.25MG; 6.25MG; 6.25MG; 6.25MG	N022063	002	Jun 20, 2017	Jan CTEC
AB2	+	9.375MG; 9.375MG; 9.375MG; 9.375MG	N022063	003	Jun 20, 2017	Jan CTEC
AB2	+	12.5MG; 12.5MG; 12.5MG; 12.5MG	N022063	004	Jun 20, 2017	Jan CTEC

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

>D>	AA	RISE PHARMA	5MG	A212901	001	May 22, 2020	Feb CAHN
>D>	AA		10MG	A212901	002	May 22, 2020	Feb CAHN
>A>	AA	SENORES PHARMS	5MG	A212901	001	May 22, 2020	Feb CAHN
>A>	AA		10MG	A212901	002	May 22, 2020	Feb CAHN

APIXABAN

TABLET; ORAL
APIXABAN

>A>	AB	APOTEX	2.5MG	A210091	001	Feb 16, 2024	Feb NEWA
>A>	AB		5MG	A210091	002	Feb 16, 2024	Feb NEWA

APREMILAST

TABLET; ORAL
APREMILAST

AB	MANKIND PHARMA	10MG	A211734	001	Feb 07, 2024	Jan NEWA
AB		20MG	A211734	002	Feb 07, 2024	Jan NEWA
AB		30MG	A211734	003	Feb 07, 2024	Jan NEWA

ARIPIPIRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
ARISTADA INITIO KIT

+	ALKERMES INC	675MG/2.4ML (281.25MG/ML)	N209830	001	Jun 29, 2018	Jan CPOT
---	--------------	---------------------------	---------	-----	--------------	----------

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL
LANORINAL

AA	!	SANDOZ	325MG; 50MG; 40MG	A086996	002	Oct 11, 1985	Jan CAHN
----	---	--------	-------------------	---------	-----	--------------	----------

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL
ATOMOXETINE HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	18MG	A079017	001	Sep 16, 2010	Jan CMS1
AB		25MG	A079017	002	Sep 16, 2010	Jan CMS1
AB		40MG	A079017	003	Sep 16, 2010	Jan CMS1
AB		60MG	A079017	004	Sep 16, 2010	Jan CMS1
AB		80MG	A079017	005	Sep 16, 2010	Jan CMS1
AB		100MG	A079017	006	Sep 16, 2010	Jan CMS1

ATORVASTATIN CALCIUM

TABLET; ORAL
ATORVASTATIN CALCIUM

AB	ANBISON LAB	EQ 10MG BASE	A211886	001	Jan 25, 2024	Jan NEWA	
AB		EQ 20MG BASE	A211886	002	Jan 25, 2024	Jan NEWA	
AB		EQ 40MG BASE	A211886	003	Jan 25, 2024	Jan NEWA	
AB		EQ 80MG BASE	A211886	004	Jan 25, 2024	Jan NEWA	
>A>	AB	AUROBINDO PHARMA LTD	EQ 10MG BASE	A217118	001	Feb 13, 2024	Feb NEWA
>A>	AB		EQ 20MG BASE	A217118	002	Feb 13, 2024	Feb NEWA
>A>	AB		EQ 40MG BASE	A217118	003	Feb 13, 2024	Feb NEWA
>A>	AB		EQ 80MG BASE	A217118	004	Feb 13, 2024	Feb NEWA
AB	LAURUS	EQ 10MG BASE	A214513	001	Jan 22, 2024	Jan NEWA	
AB		EQ 20MG BASE	A214513	002	Jan 22, 2024	Jan NEWA	
AB		EQ 40MG BASE	A214513	003	Jan 22, 2024	Jan NEWA	
AB		EQ 80MG BASE	A214513	004	Jan 22, 2024	Jan NEWA	

AVACINCAPTAD PEGOL SODIUM

SOLUTION; INTRAVITREAL
IZERVAY

+	!	ASTELLAS	EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML)	N217225	001	Aug 04, 2023	Jan CAHN
---	---	----------	---------------------------------------	---------	-----	--------------	----------

AZITHROMYCIN

TABLET; ORAL
AZITHROMYCIN

>D>	AB	YUNG SHIN PHARM	EQ 250MG BASE	A211317	001	Jul 26, 2022	Feb DISC
>A>		@	EQ 250MG BASE	A211317	001	Jul 26, 2022	Feb DISC

BACLOFEN

INJECTABLE; INTRATHECAL
BACLOFEN

@	ACIC PHARMS	0.5MG/ML	A216309	001	Aug 10, 2023	Jan DISC
@		2MG/ML	A216309	002	Aug 10, 2023	Jan DISC

TABLET; ORAL
BACLOFEN

>D>		RUBICON	15MG	A209102	004	Feb 05, 2024	Feb CTEC
>A>	AB		15MG	A209102	004	Feb 05, 2024	Feb CTEC
			15MG	A209102	004	Feb 05, 2024	Jan NEWA

	TABLET;ORAL								
	BACLOFEN								
>A>	AB	ZYDUS	15MG	A211659	004	Feb 13, 2024	Feb	NEWA	
	<u>BERDAZIMER SODIUM</u>								
	GEL;TOPICAL								
	ZELSUVMI								
	+!	LNHC	EQ 10.3% BASE	N217424	001	Jan 05, 2024	Jan	NEWA	
	<u>BETAMETHASONE DIPROPIONATE</u>								
	OINTMENT, AUGMENTED;TOPICAL								
	BETAMETHASONE DIPROPIONATE								
	@	PADAGIS US	EQ 0.05% BASE	A206118	001	Nov 09, 2017	Jan	CAHN	
	<u>BICALUTAMIDE</u>								
	TABLET;ORAL								
	BICALUTAMIDE								
	AB	CHARTWELL RX	50MG	A091011	001	Jun 10, 2015	Jan	CAHN	
>D>	@	MYLAN	50MG	A079185	001	Jul 06, 2009	Feb	CAHN	
>A>	@	RISING	50MG	A079185	001	Jul 06, 2009	Feb	CAHN	
	<u>BIRCH TRITERPENES</u>								
	GEL;TOPICAL								
	FILSUVEZ								
	+!	CHIESI	10%	N215064	001	Dec 18, 2023	Jan	CAHN	
	<u>BISOPROLOL FUMARATE</u>								
	TABLET;ORAL								
	BISOPROLOL FUMARATE								
	AB	HARMAN FINOCHEM	5MG	A217617	001	Jan 18, 2024	Jan	NEWA	
	AB		10MG	A217617	002	Jan 18, 2024	Jan	NEWA	
	<u>BLEOMYCIN SULFATE</u>								
	INJECTABLE; INJECTION								
	BLEOMYCIN SULFATE								
	@	TEVA PHARMS USA	EQ 15 UNITS BASE/VIAL	A065033	001	Jun 27, 2000	Jan	DISC	
	@		EQ 30 UNITS BASE/VIAL	A065033	002	Jun 27, 2000	Jan	DISC	
	<u>BRIMONIDINE TARTRATE</u>								
	SOLUTION/DROPS;OPHTHALMIC								
	BRIMONIDINE TARTRATE								
>A>	AB	SANDOZ	0.1%	A203172	001	Mar 04, 2024	Feb	NEWA	
	<u>BROMFENAC SODIUM</u>								
	SOLUTION/DROPS;OPHTHALMIC								
	BROMFENAC SODIUM								
	AB	LUPIN LTD	EQ 0.075% ACID	A211239	001	Feb 02, 2024	Jan	NFTG	
		BROMSITE							
	AB	+!	SUN PHARM	EQ 0.075% ACID	N206911	001	Apr 08, 2016	Jan	CFTG
	<u>BUDESONIDE</u>								
>A>	SUSPENSION;ORAL								
>A>	EOHILIA								
>A>	+!	TAKEDA PHARMS USA	2MG/10ML	N213976	001	Feb 09, 2024	Feb	NEWA	
	<u>BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE</u>								
	INJECTABLE; INJECTION								
	VIVACAINE								
	!	SEPTODONT	0.5%;0.0091MG/ML	A077250	001	Sep 27, 2006	Jan	CTNA	
	<u>BUPRENORPHINE HYDROCHLORIDE</u>								
	INJECTABLE; INJECTION								
	BUPRENORPHINE HYDROCHLORIDE								
	@	AM REGENT	EQ 0.3MG BASE/ML	A078331	001	Mar 27, 2007	Jan	DISC	
	<u>BUPROPION HYDROCHLORIDE</u>								
	TABLET, EXTENDED RELEASE;ORAL								
	BUPROPION HYDROCHLORIDE								
>D>	AB1	ANCHEN PHARMS	100MG	A091459	001	Jun 09, 2011	Feb	DISC	
>A>	@		100MG	A091459	001	Jun 09, 2011	Feb	DISC	
>D>	AB1		150MG	A091459	002	Jun 09, 2011	Feb	DISC	

TABLET, EXTENDED RELEASE;ORAL
BUPROPION HYDROCHLORIDE

>A>	@	150MG	A091459	002	Jun 09, 2011	Feb	DISC
>D>	AB2	150MG	A091520	001	Jun 09, 2011	Feb	DISC
>A>	@	150MG	A091520	001	Jun 09, 2011	Feb	DISC
>D>	AB1	200MG	A091459	003	Jun 09, 2011	Feb	DISC
>A>	@	200MG	A091459	003	Jun 09, 2011	Feb	DISC
>D>	@ MYLAN	150MG	A090941	001	May 03, 2010	Feb	CAHN
>A>	@ RISING	150MG	A090941	001	May 03, 2010	Feb	CAHN

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL
BUSPIRONE HYDROCHLORIDE

AB	AIPING PHARM INC	5MG	A202087	001	Dec 16, 2015	Jan	CAHN
AB		10MG	A202087	002	Dec 16, 2015	Jan	CAHN
AB		15MG	A202087	003	Dec 16, 2015	Jan	CAHN
AB		30MG	A202087	004	Dec 16, 2015	Jan	CAHN

CAPECITABINE

TABLET;ORAL
CAPECITABINE

>A>	AB	HETERO LABS LTD V	150MG	A210203	001	Mar 05, 2024	Feb	NEWA
>A>	AB		500MG	A210203	002	Mar 05, 2024	Feb	NEWA

CAPTOPRIL

TABLET;ORAL
CAPTOPRIL

>D>	AB	KENTON	12.5MG	A074677	004	May 30, 1997	Feb	CAHN
>D>	AB		25MG	A074677	002	May 30, 1997	Feb	CAHN
>D>	AB		50MG	A074677	001	May 30, 1997	Feb	CAHN
>D>	AB		100MG	A074677	003	May 30, 1997	Feb	CAHN
>A>	AB	STASON PHARMS	12.5MG	A074677	004	May 30, 1997	Feb	CAHN
>A>	AB		25MG	A074677	002	May 30, 1997	Feb	CAHN
>A>	AB		50MG	A074677	001	May 30, 1997	Feb	CAHN
>A>	AB		100MG	A074677	003	May 30, 1997	Feb	CAHN

CARBAMAZEPINE

TABLET;ORAL
CARBAMAZEPINE

>A>	AB	BIONPHARMA	200MG	A218221	001	Feb 16, 2024	Feb	NEWA
-----	----	------------	-------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;ORAL
CARBAMAZEPINE

>D>	AB	AMNEAL PHARMS	100MG	A212704	001	Sep 22, 2023	Feb	DISC
>A>	@		100MG	A212704	001	Sep 22, 2023	Feb	DISC
>D>	AB		200MG	A212704	002	Sep 22, 2023	Feb	DISC
>A>	@		200MG	A212704	002	Sep 22, 2023	Feb	DISC
>D>	AB		400MG	A212704	003	Sep 22, 2023	Feb	DISC
>A>	@		400MG	A212704	003	Sep 22, 2023	Feb	DISC

CARBOPROST TROMETHAMINE

INJECTABLE;INJECTION
CARBOPROST TROMETHAMINE

AP	ANI PHARMS	EQ 0.25MG BASE/ML	A215901	001	Jan 25, 2024	Jan	NEWA
----	------------	-------------------	---------	-----	--------------	-----	------

CARMUSTINE

INJECTABLE;INJECTION
CARMUSTINE

>D>	AP	INGENUS PHARMS LLC	100MG/VIAL	A211011	001	Jun 21, 2022	Feb	DISC
>A>	@		100MG/VIAL	A211011	001	Jun 21, 2022	Feb	DISC

CARVEDILOL

TABLET;ORAL
CARVEDILOL

@	SUN PHARM INDS LTD	3.125MG	A076989	001	Sep 05, 2007	Jan	DISC
@		6.25MG	A076989	002	Sep 05, 2007	Jan	DISC
@		12.5MG	A076989	003	Sep 05, 2007	Jan	DISC
@		25MG	A076989	004	Sep 05, 2007	Jan	DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

QILU EQ 3GM BASE/VIAL A203661 003 Jan 24, 2024 Jan NEWA

>A> CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM

>A> POWDER; INTRAVENOUS
>A> EXBLIFEP

>A> +! ALLECRA THERAPS EQ 2GM BASE/VIAL; 0.5GM/VIAL N216165 001 Feb 22, 2024 Feb NEWA

CEFOTAXIME SODIUM

INJECTABLE; INJECTION
CLAFORAN

+ @ STERIMAX EQ 500MG BASE/VIAL N050547 001 Jan CAHN

+ @ EQ 1GM BASE/VIAL N050547 002 Jan CAHN

+ @ EQ 2GM BASE/VIAL N050547 003 Jan CAHN

+ @ EQ 10GM BASE/VIAL N050547 004 Dec 29, 1983 Jan CAHN

CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER

@ STERIMAX EQ 20MG BASE/ML N050596 002 May 20, 1985 Jan CAHN

@ EQ 40MG BASE/ML N050596 004 May 20, 1985 Jan CAHN

CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@ STERIMAX EQ 20MG BASE/ML N050596 001 May 20, 1985 Jan CAHN

@ EQ 40MG BASE/ML N050596 003 May 20, 1985 Jan CAHN

CEFOTETAN DISODIUM

INJECTABLE; INJECTION
CEFOTAN

>D> + @ PAI HOLDINGS PHARM EQ 1GM BASE/VIAL N050588 001 Dec 27, 1985 Feb CMFD

>A> AP + EQ 1GM BASE/VIAL N050588 001 Dec 27, 1985 Feb CMFD

>D> + @ EQ 2GM BASE/VIAL N050588 002 Dec 27, 1985 Feb CMFD

>A> AP + EQ 2GM BASE/VIAL N050588 002 Dec 27, 1985 Feb CMFD

CEFOTETAN

>D> ! FRESENIUS KABI USA EQ 1GM BASE/VIAL A065374 001 Aug 09, 2007 Feb CTEC

>A> AP ! EQ 1GM BASE/VIAL A065374 001 Aug 09, 2007 Feb CTEC

>D> ! EQ 2GM BASE/VIAL A065374 002 Aug 09, 2007 Feb CTEC

>A> AP ! EQ 2GM BASE/VIAL A065374 002 Aug 09, 2007 Feb CTEC

CEFTRIAXONE SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS
CEFTRIAXONE

AP DEVA HOLDING AS EQ 250MG BASE/VIAL A210197 001 Jan 12, 2024 Jan NEWA

AP EQ 500MG BASE/VIAL A210197 002 Jan 12, 2024 Jan NEWA

AP EQ 1GM BASE/VIAL A210197 003 Jan 12, 2024 Jan NEWA

AP EQ 2GM BASE/VIAL A210197 004 Jan 12, 2024 Jan NEWA

CETIRIZINE HYDROCHLORIDE

>A> SOLUTION; ORAL

>A> CETIRIZINE HYDROCHLORIDE

>A> @ ACTAVIS MID ATLANTIC 5MG/5ML A078617 001 Feb 02, 2010 Feb CDFR

>A> AA AMNEAL PHARMS 5MG/5ML A090766 001 Oct 07, 2009 Feb CDFR

>A> @ APOZEAL PHARMS 5MG/5ML A078870 001 Apr 27, 2009 Feb CDFR

>A> @ AUROBINDO PHARMA LTD 5MG/5ML A090751 001 Dec 16, 2009 Feb CDFR

>A> AA BAJAJ 5MG/5ML A090191 001 Nov 12, 2009 Feb CDFR

>A> AA BIONPHARMA 5MG/5ML A078488 001 Oct 06, 2008 Feb CDFR

>A> AA CHARTWELL MOLECULAR 5MG/5ML A078876 001 May 11, 2012 Feb CDFR

>A> @ LANNETT CO INC 5MG/5ML A078496 001 Sep 25, 2009 Feb CDFR

>A> AA ! PADAGIS US 5MG/5ML A078398 001 Jun 17, 2008 Feb CDFR

>A> AA PHARM ASSOC 5MG/5ML A078412 001 Jun 18, 2008 Feb CDFR

>A> @ RANBAXY LABS LTD 5MG/5ML A077472 001 Jun 18, 2008 Feb CDFR

>A> AA TARO 5MG/5ML A076601 001 Jun 20, 2008 Feb CDFR

>A> AA TEVA PHARMS 5MG/5ML A077279 001 May 27, 2008 Feb CDFR

>A> @ WOCKHARDT 5MG/5ML A078757 001 Aug 28, 2009 Feb CDFR

>A> ZYRTEC

>A> @ J AND J CONSUMER INC 5MG/5ML N020346 001 Sep 27, 1996 Feb CDFR

>D> SYRUP; ORAL

>D> CETIRIZINE HYDROCHLORIDE

>D> @ ACTAVIS MID ATLANTIC 5MG/5ML A078617 001 Feb 02, 2010 Feb CDFR

>D> AA AMNEAL PHARMS 5MG/5ML A090766 001 Oct 07, 2009 Feb CDFR

>D> @ APOZEAL PHARMS 5MG/5ML A078870 001 Apr 27, 2009 Feb CDFR

>D> @ AUROBINDO PHARMA LTD 5MG/5ML A090751 001 Dec 16, 2009 Feb CDFR

>D> AA BAJAJ 5MG/5ML A090191 001 Nov 12, 2009 Feb CDFR

>D>	SYRUP;ORAL								
>D>	CETIRIZINE HYDROCHLORIDE								
>D> AA	BIONPHARMA	5MG/5ML	A 078488	001	Oct 06, 2008	Feb	CDFR		
>D> AA	CHARTWELL MOLECULAR	5MG/5ML	A 078876	001	May 11, 2012	Feb	CDFR		
>D>	@ LANNETT CO INC	5MG/5ML	A 078496	001	Sep 25, 2009	Feb	CDFR		
>D> AA	! PADAGIS US	5MG/5ML	A 078398	001	Jun 17, 2008	Feb	CDFR		
>D> AA	PHARM ASSOC	5MG/5ML	A 078412	001	Jun 18, 2008	Feb	CDFR		
AA		5MG/5ML	A 078412	001	Jun 18, 2008	Jan	CMFD		
>D>	@ RANBAXY LABS LTD	5MG/5ML	A 077472	001	Jun 18, 2008	Feb	CDFR		
>D> AA	TARO	5MG/5ML	A 076601	001	Jun 20, 2008	Feb	CDFR		
>D> AA	TEVA PHARMS	5MG/5ML	A 077279	001	May 27, 2008	Feb	CDFR		
>D>	@ WOCKHARDT	5MG/5ML	A 078757	001	Aug 28, 2009	Feb	CDFR		
>D>	ZYRTEC								
>D>	@ J AND J CONSUMER INC	5MG/5ML	N 020346	001	Sep 27, 1996	Feb	CDFR		
>D>	<u>CHLORAMPHENICOL SODIUM SUCCINATE</u>								
>D>	INJECTABLE;INJECTION								
>D>	CHLORAMPHENICOL SODIUM SUCCINATE								
>D>	! FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A 062365	001	Aug 25, 1982	Feb	DISC		
>A>	@	EQ 1GM BASE/VIAL	A 062365	001	Aug 25, 1982	Feb	DISC		
	<u>CHLORPROMAZINE HYDROCHLORIDE</u>								
	TABLET;ORAL								
	CHLORPROMAZINE HYDROCHLORIDE								
>D> AB	CHARTWELL RX	10MG	A 212630	001	Nov 29, 2021	Feb	CAHN		
>D> AB		25MG	A 212630	002	Nov 29, 2021	Feb	CAHN		
>D> AB		50MG	A 212630	003	Nov 29, 2021	Feb	CAHN		
>D> AB		100MG	A 212630	004	Nov 29, 2021	Feb	CAHN		
>D> AB		200MG	A 212630	005	Nov 29, 2021	Feb	CAHN		
>A> AB	ZAMEER PHARMS	10MG	A 212630	001	Nov 29, 2021	Feb	CAHN		
>A> AB		25MG	A 212630	002	Nov 29, 2021	Feb	CAHN		
>A> AB		50MG	A 212630	003	Nov 29, 2021	Feb	CAHN		
>A> AB		100MG	A 212630	004	Nov 29, 2021	Feb	CAHN		
>A> AB		200MG	A 212630	005	Nov 29, 2021	Feb	CAHN		
	<u>CHLORZOXAZONE</u>								
	TABLET;ORAL								
	CHLORZOXAZONE								
>D> AA	HAVIX	500MG	A 210961	001	Jan 22, 2024	Feb	CAHN		
AA		500MG	A 210961	001	Jan 22, 2024	Jan	NEWA		
>D> AA	RISE PHARMA	250MG	A 215158	001	Jul 29, 2021	Feb	CAHN		
>A> AA	SENORES PHARMS	250MG	A 215158	001	Jul 29, 2021	Feb	CAHN		
>A> AA		500MG	A 210961	001	Jan 22, 2024	Feb	CAHN		
	<u>CHOLINE FENOFIBRATE</u>								
	CAPSULE, DELAYED RELEASE;ORAL								
	FENOFIBRIC ACID								
>A> AB	MACLEODS PHARMS LTD	EQ 45MG FENOFIBRIC ACID	A 207796	001	Feb 08, 2024	Feb	NEWA		
>A> AB		EQ 135MG FENOFIBRIC ACID	A 207796	002	Feb 08, 2024	Feb	NEWA		
	<u>CICLOPIROX</u>								
	CREAM;TOPICAL								
	CICLOPIROX								
AB	TARO	0.77%	A 076790	001	Apr 12, 2005	Jan	CAHN		
	<u>CILOSTAZOL</u>								
	TABLET;ORAL								
	CILOSTAZOL								
>D>	@ MYLAN	50MG	A 077323	002	Apr 20, 2006	Feb	CAHN		
>D>	@	100MG	A 077323	001	Apr 20, 2006	Feb	CAHN		
>A>	@ RISING	50MG	A 077323	002	Apr 20, 2006	Feb	CAHN		
>A>	@	100MG	A 077323	001	Apr 20, 2006	Feb	CAHN		
>D>	<u>CIMETIDINE HYDROCHLORIDE</u>								
>D>	SOLUTION;ORAL								
>D>	CIMETIDINE HYDROCHLORIDE								
>D> AA	! PAI HOLDINGS PHARM	EQ 300MG BASE/5ML	A 074664	001	Oct 28, 1997	Feb	DISC		
>A>	@	EQ 300MG BASE/5ML	A 074664	001	Oct 28, 1997	Feb	DISC		
>D> AA	PHARM ASSOC	EQ 300MG BASE/5ML	A 074553	001	Jan 27, 1997	Feb	DISC		
>A>	@	EQ 300MG BASE/5ML	A 074553	001	Jan 27, 1997	Feb	DISC		

CITALOPRAM HYDROBROMIDE

TABLET; ORAL		CITALOPRAM HYDROBROMIDE					
AB	APOTEX	EQ 10MG BASE		A 077046	001	Nov 24, 2004	Jan CAHN
AB		EQ 20MG BASE		A 077046	002	Nov 24, 2004	Jan CAHN
AB		EQ 40MG BASE		A 077046	003	Nov 24, 2004	Jan CAHN
	@ TARO	EQ 10MG BASE		A 077278	001	Mar 22, 2006	Jan CAHN
	@	EQ 20MG BASE		A 077278	002	Mar 22, 2006	Jan CAHN
	@	EQ 40MG BASE		A 077278	003	Mar 22, 2006	Jan CAHN

CLEMASTINE FUMARATE

SYRUP; ORAL		CLEMASTINE FUMARATE					
	@ NEW HEIGHTS	EQ 0.5MG BASE/5ML		A 074884	001	Dec 17, 1997	Jan CAHN

CLINDAMYCIN PHOSPHATE

GEL; TOPICAL		CLINDAMYCIN PHOSPHATE					
>D>	AB1 AMNEAL	EQ 1% BASE		A 215219	001	Nov 03, 2022	Feb DISC
>A>	@	EQ 1% BASE		A 215219	001	Nov 03, 2022	Feb DISC
GEL; VAGINAL		XACIATO					
	+! ORGANON LLC	EQ 2% BASE		N 215650	001	Dec 07, 2021	Jan CAHN

CLOBAZAM

TABLET; ORAL		CLOBAZAM					
	@ BRECKENRIDGE	20MG		A 209308	002	Oct 22, 2018	Jan DISC

CLONIDINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL		CLONIDINE HYDROCHLORIDE					
	@ BLUEPHARMA INDUSTRIA	0.1MG		A 211433	001	Oct 12, 2018	Jan CAHN

CLOTRIMAZOLE

TROCHE/LOZENGE; ORAL		CLOTRIMAZOLE					
>A>	AB THINQ PHARM-CRO PVT	10MG		A 215641	001	Feb 29, 2024	Feb NEWA

COBICISTAT

TABLET; ORAL		COBICISTAT					
AB	MYLAN LABS LTD	150MG		A 209986	001	Feb 07, 2024	Jan NFTG
AB	+! GILEAD SCIENCES INC	150MG		N 203094	001	Sep 24, 2014	Jan CFTG

COCAINE HYDROCHLORIDE

SOLUTION; NASAL		GOPRELTO					
	+! NODEN PHARMA	4%		N 209963	001	Dec 14, 2017	Jan CAHN

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION		CYCLOPHOSPHAMIDE					
AP	HIKMA	500MG/VIAL		A 216958	001	Dec 18, 2023	Jan CAHN
AP		1GM/VIAL		A 216958	002	Dec 18, 2023	Jan CAHN
AP		2GM/VIAL		A 216958	003	Dec 18, 2023	Jan CAHN
SOLUTION; INTRAVENOUS		CYCLOPHOSPHAMIDE					
	+ @ BAXTER HLTHCARE CORP	500MG/2.5ML (200MG/ML)		N 217651	001	Jun 28, 2023	Jan CAHN
	+ @	1GM/5ML (200MG/ML)		N 217651	002	Jun 28, 2023	Jan CAHN

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL		CYPROHEPTADINE HYDROCHLORIDE					
>D>	AA PHARM ASSOC	2MG/5ML		A 091295	001	Mar 28, 2013	Feb DISC
>A>	@	2MG/5ML		A 091295	001	Mar 28, 2013	Feb DISC

CYSTEINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS
ELCYS

+ @ EXELA PHARMA 2500MG/50ML (50MG/ML) N210660 002 Dec 04, 2023 Jan DISC

DACTINOMYCIN

INJECTABLE; INJECTION
COSMEGEN

+ @ RECORDATI RARE 0.5MG/VIAL N050682 001 Jan DISC

AP ! EUGIA PHARMA 0.5MG/VIAL A203385 001 Nov 09, 2017 Jan CHRS

DAPSONE

GEL; TOPICAL
DAPSONE

@ PADAGIS ISRAEL 5% A215087 001 Oct 31, 2023 Jan DISC

@ 7.5% A212657 001 Nov 01, 2023 Jan DISC

DEFLAZACORT

TABLET; ORAL

>A> DEFLAZACORT

>A> AB AUROBINDO PHARMA LTD 6MG A217123 001 Feb 09, 2024 Feb NFTG

>A> AB 18MG A217123 002 Feb 09, 2024 Feb NFTG

>A> AB 30MG A217123 003 Feb 09, 2024 Feb NFTG

>A> AB 36MG A217123 004 Feb 09, 2024 Feb NFTG

EMFLAZA

>D> + PTC THERAP 6MG N208684 001 Feb 09, 2017 Feb CFTG

>A> AB + 6MG N208684 001 Feb 09, 2017 Feb CFTG

>D> + 18MG N208684 002 Feb 09, 2017 Feb CFTG

>A> AB + 18MG N208684 002 Feb 09, 2017 Feb CFTG

>D> + 30MG N208684 003 Feb 09, 2017 Feb CFTG

>A> AB + 30MG N208684 003 Feb 09, 2017 Feb CFTG

>D> +! 36MG N208684 004 Feb 09, 2017 Feb CFTG

>A> AB +! 36MG N208684 004 Feb 09, 2017 Feb CFTG

DEOXYCHOLIC ACID

SOLUTION; SUBCUTANEOUS
KYBELLA

AP +! ABBVIE 20MG/2ML (10MG/ML) N206333 001 Apr 29, 2015 Jan CAHN

DESLORATADINE

TABLET; ORAL

DESLORATADINE @ CHARTWELL RX 5MG A078364 001 Dec 03, 2010 Jan CAHN

DESMOPRESSIN ACETATE

TABLET; ORAL

DESMOPRESSIN ACETATE

>D> AB ACTAVIS LABS FL INC 0.1MG A076470 001 Jul 01, 2005 Feb DISC

>A> @ 0.1MG A076470 001 Jul 01, 2005 Feb DISC

>D> AB 0.2MG A076470 002 Jul 01, 2005 Feb DISC

>A> @ 0.2MG A076470 002 Jul 01, 2005 Feb DISC

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE @ AKORN 0.05% A203787 001 Jan 06, 2017 Feb CAHN

>D> @ 0.25% A203234 001 Jun 12, 2015 Feb CAHN

>A> @ SAPTALIS PHARMS 0.05% A203787 001 Jan 06, 2017 Feb CAHN

>A> @ 0.25% A203234 001 Jun 12, 2015 Feb CAHN

DEXAMETHASONE

TABLET; ORAL

DEXAMETHASONE @ PANGEA 0.25MG A088149 001 Apr 28, 1983 Jan CAHN

AB ZYDUS PHARMS 0.5MG A216282 001 Feb 07, 2024 Jan NEWA

AB 0.75MG A216282 002 Feb 07, 2024 Jan NEWA

AB 1.5MG A216282 003 Feb 07, 2024 Jan NEWA

AB 2MG A216283 001 Feb 07, 2024 Jan NEWA

AB 4MG A216282 004 Feb 07, 2024 Jan NEWA

AB 6MG A216282 005 Feb 07, 2024 Jan NEWA

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE

>D>	AP	GENEYORK PHARMS	EQ 4MG PHOSPHATE/ML	A214891	001	Jul 28, 2023	Feb	DISC
>A>		@	EQ 4MG PHOSPHATE/ML	A214891	001	Jul 28, 2023	Feb	DISC
>D>	AP		EQ 10MG PHOSPHATE/ML	A214890	001	Jul 07, 2023	Feb	DISC
>A>		@	EQ 10MG PHOSPHATE/ML	A214890	001	Jul 07, 2023	Feb	DISC

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL
DEXLANSOPRAZOLE

AB		MYLAN	30MG	A205205	001	Jan 19, 2024	Jan	NEWA
AB			60MG	A205205	002	Jan 19, 2024	Jan	NEWA

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
DEXTROAMPHETAMINE SULFATE

		@ TRIS PHARMA INC	5MG	A206095	001	Aug 18, 2022	Jan	DISC
		@	10MG	A206095	002	Aug 18, 2022	Jan	DISC

DIAZEPAM

INJECTABLE; INJECTION
DIAZEPAM

		@ HIKMA	5MG/ML (5MG/ML)	A070311	002	Dec 16, 1985	Jan	NEWA
		@	10MG/2ML (5MG/ML)	A070311	003	Dec 16, 1985	Jan	NEWA
AP			50MG/10ML (5MG/ML)	A070311	001	Dec 16, 1985	Jan	C POT

DICHLORPHENAMIDE

TABLET; ORAL
DICHLORPHENAMIDE

>D>								
>D>	AB	TORRENT	50MG	A215924	001	Dec 29, 2022	Feb	CTNA
>A>		ORMALVI						
>A>	AB	TORRENT	50MG	A215924	001	Dec 29, 2022	Feb	CTNA

DIGOXIN

ELIXIR; ORAL
DIGOXIN

>D>	AA	NOVITIUM PHARMA	0.05MG/ML	A213000	001	Oct 04, 2019	Feb	CAHN
>A>	AA	VISTAPHARM LLC	0.05MG/ML	A213000	001	Oct 04, 2019	Feb	CAHN

DIHYDROERGOTAMINE MESYLATE

SPRAY, METERED; NASAL
TRUDHESA

>D>		+! IMPEL PHARMS	0.725MG/SPRAY	N213436	001	Sep 02, 2021	Feb	CAHN
>A>		+! JN BIDCO	0.725MG/SPRAY	N213436	001	Sep 02, 2021	Feb	CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
DILTIAZEM HYDROCHLORIDE

>D>	AB3	SUN PHARM	360MG	A090492	005	Oct 28, 2011	Feb	DISC
>A>		@	360MG	A090492	005	Oct 28, 2011	Feb	DISC

DIPYRIDAMOLE

TABLET; ORAL
DIPYRIDAMOLE

		@ GENUS	25MG	A040898	001	Apr 23, 2008	Jan	CAHN
		@	50MG	A040898	002	Apr 23, 2008	Jan	CAHN
		@	75MG	A040898	003	Apr 23, 2008	Jan	CAHN

DOCETAXEL

INJECTABLE; INJECTION
DOCETAXEL

>A>	AP	ACIC PHARMS	80MG/4ML (20MG/ML)	A216677	002	Feb 28, 2024	Feb	NEWA
>A>	AP		20MG/ML (20MG/ML)	A216677	001	Feb 28, 2024	Feb	NEWA

SOLUTION; INTRAVENOUS
DOCETAXEL

		+ @ AVYXA HOLDINGS	20MG/2ML (10MG/ML)	N215813	001	Nov 22, 2022	Jan	CAHN
		+ @	80MG/8ML (10MG/ML)	N215813	002	Nov 22, 2022	Jan	CAHN
		+ @	160MG/16ML (10MG/ML)	N215813	003	Nov 22, 2022	Jan	CAHN

DOLUTEGRAVIR SODIUMTABLET; ORAL
TIVICAY

+ @	VIIV HLTHCARE	EQ 10MG BASE	N204790	002	Jun 09, 2016	Jan	DISC
+ @		EQ 25MG BASE	N204790	003	Jun 09, 2016	Jan	DISC

DOXERCALCIFEROLINJECTABLE; INJECTION
DOXERCALCIFEROL

	@ AMNEAL	2MCG/ML (2MCG/ML)	A208974	001	May 24, 2017	Jan	DISC
	@	4MCG/2ML (2MCG/ML)	A208974	002	May 24, 2017	Jan	DISC
AP		4MCG/2ML (2MCG/ML)	A208975	001	May 24, 2017	Jan	CMFD

DOXYCYCLINE HYCLATECAPSULE; ORAL
ACTICLATE CAP

+ @	CHARTWELL RX	EQ 75MG BASE	N208253	001	Apr 26, 2016	Jan	CAHN
-----	--------------	--------------	---------	-----	--------------	-----	------

TABLET; ORAL
ACTICLATE

AB	+ CHARTWELL RX	EQ 75MG BASE	N205931	001	Jul 25, 2014	Jan	CAHN
AB	+!	EQ 150MG BASE	N205931	002	Jul 25, 2014	Jan	CAHN

TABLET, DELAYED RELEASE; ORAL
DORYX

>D>	AB	+ MAYNE PHARMA	EQ 75MG BASE	N050795	001	May 06, 2005	Feb	DISC
>A>		+ @	EQ 75MG BASE	N050795	001	May 06, 2005	Feb	DISC
>D>	AB	+	EQ 150MG BASE	N050795	003	Jun 20, 2008	Feb	DISC
>A>		+ @	EQ 150MG BASE	N050795	003	Jun 20, 2008	Feb	DISC

DRONEDARONE HYDROCHLORIDETABLET; ORAL
DRONEDARONE HYDROCHLORIDE

AB	LUPIN	EQ 400MG BASE	A205904	001	Jan 31, 2024	Jan	NFTG	
AB	+!	SANOFI AVENTIS US	EQ 400MG BASE	N022425	001	Jul 01, 2009	Jan	CFTG

DULOXETINE HYDROCHLORIDECAPSULE, DELAYED REL PELLETS; ORAL
DULOXETINE HYDROCHLORIDE

>D>	AB	ANCHEN PHARMS	EQ 20MG BASE	A090780	001	Oct 28, 2015	Feb	DISC
>A>		@	EQ 20MG BASE	A090780	001	Oct 28, 2015	Feb	DISC
>D>	AB		EQ 30MG BASE	A090780	002	Oct 28, 2015	Feb	DISC
>A>		@	EQ 30MG BASE	A090780	002	Oct 28, 2015	Feb	DISC
>D>	AB		EQ 60MG BASE	A090780	003	Oct 28, 2015	Feb	DISC
>A>		@	EQ 60MG BASE	A090780	003	Oct 28, 2015	Feb	DISC
>D>	AB	MARKSANS PHARMA	EQ 20MG BASE	A090723	001	Dec 11, 2013	Feb	DISC
>A>		@	EQ 20MG BASE	A090723	001	Dec 11, 2013	Feb	DISC
>D>	AB		EQ 30MG BASE	A090723	002	Dec 11, 2013	Feb	DISC
>A>		@	EQ 30MG BASE	A090723	002	Dec 11, 2013	Feb	DISC
>D>	AB		EQ 60MG BASE	A090723	003	Dec 11, 2013	Feb	DISC
>A>		@	EQ 60MG BASE	A090723	003	Dec 11, 2013	Feb	DISC

DUTASTERIDECAPSULE; ORAL
DUTASTERIDE

>D>	AB	VINTAGE	0.5MG	A202421	001	Nov 20, 2015	Feb	DISC
>A>		@	0.5MG	A202421	001	Nov 20, 2015	Feb	DISC

EPINEPHRINESOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
EPINEPHRINE

>A>	+!	BPI LABS	30MG/30ML (1MG/ML)	N205029	004	Feb 14, 2024	Feb	NEWA
-----	----	----------	--------------------	---------	-----	--------------	-----	------

EPINEPHRINE; LIDOCAINE HYDROCHLORIDEINJECTABLE; INJECTION
XYLOCAINE W/ EPINEPHRINE

>D>	@	FRESENIUS KABI USA	0.01MG/ML; 2%	N006488	003		Feb	CRLD
>A>	+ @		0.01MG/ML; 2%	N006488	003		Feb	CRLD

EPLERENONETABLET; ORAL
EPLERENONE

>D>	AB	PIRAMAL HLTHCARE UK	25MG	A212765	001	Aug 10, 2020	Feb CAHN
>D>	AB		50MG	A212765	002	Aug 10, 2020	Feb CAHN
>A>	AB	SLATE RUN PHARMA	25MG	A212765	001	Aug 10, 2020	Feb CAHN
>A>	AB		50MG	A212765	002	Aug 10, 2020	Feb CAHN

EPLONTERSEN SODIUMSOLUTION; SUBCUTANEOUS
WAINUA

>D>							
>D>	+	ASTRAZENECA AB	EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML)	N217388	001	Dec 21, 2023	Feb CTNA
	+		EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML)	N217388	001	Dec 21, 2023	Jan CAHN
>A>		WAINUA (AUTOINJECTOR)					
>A>	+	ASTRAZENECA AB	EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML)	N217388	001	Dec 21, 2023	Feb CTNA

EPOPROSTENOL SODIUMINJECTABLE; INJECTION
EPOPROSTENOL SODIUM

AP1		MEITHEAL	EQ 0.5MG BASE/VIAL	A078396	001	Apr 23, 2008	Jan CAHN
AP1			EQ 1.5MG BASE/VIAL	A078396	002	Apr 23, 2008	Jan CAHN

ERGOTAMINE TARTRATETABLET; SUBLINGUAL
ERGOMAR

>A>	!	PANGEA	2MG	A087693	001	Feb 24, 1983	Feb CAHN
>D>	!	TERSERA	2MG	A087693	001	Feb 24, 1983	Feb CAHN

ERTAPENEM SODIUMINJECTABLE; INTRAMUSCULAR, INTRAVENOUS
ERTAPENEM SODIUM

@	SUN PHARM	EQ 1GM BASE/VIAL	A209145	001	May 02, 2023	Jan DISC
---	-----------	------------------	---------	-----	--------------	----------

ESLICARBAZEPINE ACETATETABLET; ORAL
ESLICARBAZEPINE ACETATE

>A>	AB	TORRENT	200MG	A211227	001	Feb 27, 2024	Feb NEWA
>A>	AB		400MG	A211227	002	Feb 27, 2024	Feb NEWA
>A>	AB		600MG	A211227	003	Feb 27, 2024	Feb NEWA
>A>	AB		800MG	A211227	004	Feb 27, 2024	Feb NEWA

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATEINJECTABLE; INTRAMUSCULAR
LUNELLE

>D>	@	PHARMACIA AND UPJOHN	5MG/0.5ML; 25MG/0.5ML	N020874	001	Oct 05, 2000	Feb CRLD
>A>	+	@	5MG/0.5ML; 25MG/0.5ML	N020874	001	Oct 05, 2000	Feb CRLD

ETHINYL ESTRADIOL; LEVONORGESTRELTABLET; ORAL
MINZOYA

>A>	AB3	LUPIN LTD	0.02MG; 0.1MG	A217087	001	Feb 15, 2024	Feb NEWA
-----	-----	-----------	---------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATECAPSULE; ORAL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

>D>	AB	AMNEAL PHARMS	0.02MG; 1MG	A214292	001	Jul 20, 2021	Feb DISC
>A>		@	0.02MG; 1MG	A214292	001	Jul 20, 2021	Feb DISC

ETHOSUXIMIDECAPSULE; ORAL
ETHOSUXIMIDE

AB		EPIC PHARMA LLC	250MG	A040686	001	May 28, 2008	Jan CAHN
----	--	-----------------	-------	---------	-----	--------------	----------

FAMOTIDINE

FOR SUSPENSION;ORAL
FAMOTIDINE

AB CEROVENE INC 40MG/5ML A217605 001 Jan 16, 2024 Jan NEWA

FAMOTIDINE; IBUPROFEN

TABLET;ORAL
DUEXIS

>D> AB +! HORIZON 26.6MG;800MG N022519 001 Apr 23, 2011 Feb DISC
>A> + @ 26.6MG;800MG N022519 001 Apr 23, 2011 Feb DISC

IBUPROFEN AND FAMOTIDINE

>D> AB ALKEM LABS LTD 26.6MG;800MG A211890 001 Aug 03, 2021 Feb CHRS
>A> AB ! 26.6MG;800MG A211890 001 Aug 03, 2021 Feb CHRS

FEBUXOSTAT

TABLET;ORAL
FEBUXOSTAT

AB LUPIN LTD 40MG A205406 001 Jan 17, 2024 Jan NEWA
AB 80MG A205406 002 Jan 17, 2024 Jan NEWA

FEDRATINIB HYDROCHLORIDE

CAPSULE;ORAL
INREBIC

>A> +! BRISTOL-MYERS EQ 100MG BASE N212327 001 Aug 16, 2019 Feb CAHN
>D> +! IMPACT EQ 100MG BASE N212327 001 Aug 16, 2019 Feb CAHN

FENOFIBRATE

CAPSULE;ORAL
FENOFIBRATE (MICRONIZED)

AB YOUNGTECH PHARMS INC 67MG A211407 001 Jan 31, 2024 Jan NEWA
AB 134MG A211407 002 Jan 31, 2024 Jan NEWA
AB 200MG A211407 003 Jan 31, 2024 Jan NEWA

FIDAXOMICIN

TABLET;ORAL
DIFICID

AB +! CUBIST PHARMS LLC 200MG N201699 001 May 27, 2011 Jan CFTG
AB FIDAXOMICIN
AB ACTAVIS LABS FL 200MG A208443 001 Jan 16, 2024 Jan NEWA

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL
FINGOLIMOD HYDROCHLORIDE

>A> AB AUROBINDO PHARMA LTD EQ 0.5MG BASE A207983 001 Feb 28, 2024 Feb NEWA
>D> @ BIOCON LTD EQ 0.5MG BASE A207979 001 Dec 04, 2019 Feb CMFD
>A> AB EQ 0.5MG BASE A207979 001 Dec 04, 2019 Feb CMFD

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION
FLUDARABINE PHOSPHATE

>D> @ MYLAN LABS LTD 50MG/VIAL A200648 001 Oct 16, 2012 Feb CAHN
>A> @ RISING 50MG/VIAL A200648 001 Oct 16, 2012 Feb CAHN

FLUOCINOLONE ACETONIDE

OIL;TOPICAL
FLUOCINOLONE ACETONIDE

>D> @ AKORN 0.01% A091514 001 Jun 25, 2015 Feb CAHN
>A> @ SAPTALIS PHARMS 0.01% A091514 001 Jun 25, 2015 Feb CAHN
AT TARO 0.01% A209336 001 May 19, 2016 Jan CAHN

OIL/DROPS;OTIC

FLUOCINOLONE ACETONIDE

>D> @ AKORN 0.01% A202705 001 Sep 09, 2016 Feb CAHN
>A> @ SAPTALIS PHARMS 0.01% A202705 001 Sep 09, 2016 Feb CAHN

FLUOCINONIDE

CREAM;TOPICAL
FLUOCINONIDE

@ PADAGIS ISRAEL 0.1% A090256 001 Jan 14, 2014 Jan DISC

GEL;TOPICAL
 FLUOCINONIDE
 @ PADAGIS US

0.05%

A209030 001 Jun 19, 2018 Jan CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL
 FLUOXETINE HYDROCHLORIDE
 @ SUN PHARM INDS LTD

EQ 40MG BASE

A076990 001 Dec 13, 2004 Jan DISC

TABLET;ORAL
 FLUOXETINE HYDROCHLORIDE

@ TEVA EQ 10MG BASE
 @ EQ 20MG BASE
 @ TEVA PHARMS USA EQ 60MG BASE

A075872 001 Jan 29, 2002 Jan DISC
 A075872 002 Jan 04, 2019 Jan DISC
 A211051 001 Dec 03, 2018 Jan DISC

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL
 FLUPHENAZINE HYDROCHLORIDE

>D>	AB	CHARTWELL RX	1MG	A215141	001	Oct 20, 2021	Feb CAHN
>D>	AB		2.5MG	A215141	002	Oct 20, 2021	Feb CAHN
>D>	AB		5MG	A215141	003	Oct 20, 2021	Feb CAHN
>D>	AB		10MG	A215141	004	Oct 20, 2021	Feb CAHN
		@ TORRENT	1MG	A217094	001	Jan 22, 2024	Jan DISC
	AB		1MG	A217094	001	Jan 22, 2024	Jan NEWA
		@	2.5MG	A217094	002	Jan 22, 2024	Jan DISC
	AB		2.5MG	A217094	002	Jan 22, 2024	Jan NEWA
		@	5MG	A217094	003	Jan 22, 2024	Jan DISC
	AB		5MG	A217094	003	Jan 22, 2024	Jan NEWA
		@	10MG	A217094	004	Jan 22, 2024	Jan DISC
	AB		10MG	A217094	004	Jan 22, 2024	Jan NEWA
>A>	AB	ZAMEER PHARMS	1MG	A215141	001	Oct 20, 2021	Feb CAHN
>A>	AB		2.5MG	A215141	002	Oct 20, 2021	Feb CAHN
>A>	AB		5MG	A215141	003	Oct 20, 2021	Feb CAHN
>A>	AB		10MG	A215141	004	Oct 20, 2021	Feb CAHN

FLUVOXAMINE MALEATE

TABLET;ORAL
 FLUVOXAMINE MALEATE

AB	BIONPHARMA	25MG	A217917	001	Jan 22, 2024	Jan NEWA
AB		50MG	A217917	002	Jan 22, 2024	Jan NEWA
AB		100MG	A217917	003	Jan 22, 2024	Jan NEWA

FOSAMPRENAVIR CALCIUM

TABLET;ORAL
 FOSAMPRENAVIR CALCIUM

AB	! MYLAN	EQ 700MG BASE	A204060	001	Apr 15, 2016	Jan CHRS
	LEXIVA					
	+ @ VIIV HLTHCARE	EQ 700MG BASE	N021548	001	Oct 20, 2003	Jan DISC

FOSCARNET SODIUM

INJECTABLE;INJECTION
 FOSCARNET SODIUM

>A>	AP	AMNEAL	2.4GM/100ML	A216602	001	Mar 01, 2024	Feb NEWA
-----	----	--------	-------------	---------	-----	--------------	----------

GABAPENTIN

SOLUTION;ORAL
 GABAPENTIN

AA	ANNORA PHARMA	250MG/5ML	A217682	001	Jan 17, 2024	Jan NEWA
----	---------------	-----------	---------	-----	--------------	----------

TABLET;ORAL
 GABAPENTIN

AB1	ACI	600MG	A203244	002	Jul 12, 2013	Jan CTEC	
AB1		800MG	A203244	001	Jul 12, 2013	Jan CTEC	
AB1	ACTAVIS ELIZABETH	600MG	A075694	001	Oct 21, 2004	Jan CTEC	
AB1		800MG	A075694	002	Oct 21, 2004	Jan CTEC	
AB1	ALKEM LABS LTD	600MG	A206402	001	Dec 23, 2015	Jan CTEC	
AB1		800MG	A206402	002	Dec 23, 2015	Jan CTEC	
>A>	AB2	ANNORA PHARMA	300MG	A218075	001	Feb 26, 2024	Feb NEWA
>A>	AB2		600MG	A218075	002	Feb 26, 2024	Feb NEWA
AB1	APOTEX	100MG	A077894	001	Oct 10, 2006	Jan CTEC	
AB1		300MG	A077894	002	Oct 10, 2006	Jan CTEC	
AB1		400MG	A077894	003	Oct 10, 2006	Jan CTEC	
AB1	ASCENT PHARMS INC	600MG	A214957	001	Oct 01, 2021	Jan CTEC	
AB1		800MG	A214957	002	Oct 01, 2021	Jan CTEC	

TABLET; ORAL

GABAPENTIN

AB1	AUROBINDO PHARMA LTD	600MG	A200651	001	Oct 06, 2011	Jan CTEC
AB1		800MG	A200651	002	Oct 06, 2011	Jan CTEC
AB1	CSPC OUYI	600MG	A207057	001	Oct 26, 2017	Jan CTEC
AB1		800MG	A207057	002	Oct 26, 2017	Jan CTEC
AB1	GLENMARK PHARMS LTD	600MG	A077662	001	Aug 18, 2006	Jan CTEC
AB1		800MG	A077662	002	Aug 18, 2006	Jan CTEC
AB1	GRANULES	600MG	A217116	001	Mar 28, 2023	Jan CTEC
AB1		800MG	A217116	002	Mar 28, 2023	Jan CTEC
>A>	AB2 HUMANWELL	300MG	A216252	001	Feb 26, 2024	Feb NEWA
>A>	AB2	600MG	A216252	002	Feb 26, 2024	Feb NEWA
AB1	INVAGEN PHARMS	600MG	A202764	001	Oct 16, 2012	Jan CTEC
AB1		800MG	A202764	002	Oct 16, 2012	Jan CTEC
AB1	IVAX SUB TEVA PHARMS	100MG	A076017	001	Apr 28, 2004	Jan CTEC
AB1		300MG	A076017	002	Apr 28, 2004	Jan CTEC
AB1		400MG	A076017	003	Apr 28, 2004	Jan CTEC
AB1	RISING	600MG	A217995	001	Jul 19, 2023	Jan CTEC
AB1		800MG	A217995	002	Jul 19, 2023	Jan CTEC
AB1	RUBICON	600MG	A077661	004	Sep 13, 2006	Jan CTEC
AB1		800MG	A077661	005	Sep 13, 2006	Jan CTEC
AB1	SCIEGEN PHARMS INC	600MG	A205101	001	Feb 04, 2016	Jan CTEC
AB1		800MG	A205101	002	Feb 04, 2016	Jan CTEC
>A>	AB1 STRIDES PHARMA	600MG	A211313	001	Mar 04, 2024	Feb NEWA
>A>	AB1	800MG	A211313	002	Mar 04, 2024	Feb NEWA
AB1	SUN PHARM INDS LTD	600MG	A077525	001	Aug 24, 2006	Jan CTEC
AB1		800MG	A077525	002	Aug 24, 2006	Jan CTEC
AB2	ZYDUS PHARMS	300MG	A203934	001	Jan 24, 2024	Jan NEWA
AB2		600MG	A203934	002	Jan 24, 2024	Jan NEWA
AB1	ZYDUS PHARMS USA INC	600MG	A078926	001	Feb 11, 2011	Jan CTEC
AB1		800MG	A078926	002	Feb 11, 2011	Jan CTEC
GRALISE						
AB2	+! ALMATICA	300MG	N022544	001	Jan 28, 2011	Jan CTEC
AB2	+	600MG	N022544	002	Jan 28, 2011	Jan CTEC
BX	+	600MG	N022544	002	Jan 28, 2011	Jan CHRS
	+!	900MG	N022544	005	Apr 18, 2023	Jan CHRS
NEURONTIN						
AB1	+ VIATRIS	600MG	N020882	001	Oct 09, 1998	Jan CTEC
AB1	+!	800MG	N020882	002	Oct 09, 1998	Jan CTEC

GENTAMICIN SULFATE

SOLUTION/DROPS; OPHTHALMIC

GENTAK

>D>	@ AKORN	EQ 0.3% BASE	A064163	001	Oct 12, 2001	Feb CAHN
>A>	@ SAPTALIS PHARMS	EQ 0.3% BASE	A064163	001	Oct 12, 2001	Feb CAHN

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

>D>	@ HERITAGE PHARMS	1.25MG; 250MG	A079009	001	Jun 03, 2009	Feb CMFD
>A>	AB	1.25MG; 250MG	A079009	001	Jun 03, 2009	Feb CMFD
>D>	@	2.5MG; 500MG	A079009	002	Jun 03, 2009	Feb CMFD
>A>	AB	2.5MG; 500MG	A079009	002	Jun 03, 2009	Feb CMFD
>D>	@	5MG; 500MG	A079009	003	Jun 03, 2009	Feb CMFD
>A>	AB	5MG; 500MG	A079009	003	Jun 03, 2009	Feb CMFD

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

>A>	AP NIVAGEN PHARMS INC	0.2MG/ML	A212591	001	Oct 13, 2021	Feb CAHN
>D>	AP UMEDICA	0.2MG/ML	A212591	001	Oct 13, 2021	Feb CAHN

GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

PREVDUO

>A>	+! AZURITY	0.6MG/3ML (0.2MG/ML); 3MG/3ML (1MG/ML)	N216903	001	Feb 23, 2023	Feb CAHN
>D>	+! SLAYBACK PHARMA LLC	0.6MG/3ML (0.2MG/ML); 3MG/3ML (1MG/ML)	N216903	001	Feb 23, 2023	Feb CAHN

GRISEOFULVIN, MICROSIZE

		TABLET;ORAL					
		FULVICIN-U/F					
AB	CHARTWELL RX	250MG		A 060569	002	Jan	CTEC
		250MG		A 060569	002	Jan	CAIN
AB		500MG		A 060569	001	Jan	CTEC
		500MG		A 060569	001	Jan	CAIN
		GRISEOFULVIN					
AB	SANDOZ	250MG		A 091592	001	Aug 07, 2013	Jan CTEC

GRISEOFULVIN, ULTRAMICROSIZE

		TABLET;ORAL					
		FULVICIN P/G					
AB	CHARTWELL RX	125MG		A 061996	001	Jan	CTEC
		125MG		A 061996	001	Jan	CAIN
AB		250MG		A 061996	002	Jan	CTEC
		250MG		A 061996	002	Jan	CAIN
		FULVICIN P/G 165					
	CHARTWELL RX	165MG		A 061996	003	Apr 06, 1982	Jan CAIN
		FULVICIN P/G 330					
	CHARTWELL RX	330MG		A 061996	004	Apr 06, 1982	Jan CAIN

GUANFACINE HYDROCHLORIDE

		TABLET;ORAL					
		GUANFACINE HYDROCHLORIDE					
>A>	AB	XIROMED	EQ 1MG BASE	A 218326	001	Feb 23, 2024	Feb NEWA
>A>	AB		EQ 2MG BASE	A 218326	002	Feb 23, 2024	Feb NEWA

HALCINONIDE

		OINTMENT;TOPICAL					
		HALOG					
	+ @	SUN PHARM INDS INC	0.1%	N 017824	001	Jan	DISC
		SOLUTION;TOPICAL					
		HALOG					
	+ @	SUN PHARM INDS INC	0.1%	N 017823	001	Jan	DISC

HALOPERIDOL

		TABLET;ORAL					
		HALOPERIDOL					
AB	CHARTWELL RX	0.5MG		A 071209	002	Nov 17, 1986	Jan CAHN
AB		1MG		A 071209	003	Nov 17, 1986	Jan CAHN
	@	2MG		A 071209	004	Nov 17, 1986	Jan CAHN
AB		5MG		A 071209	001	Nov 17, 1986	Jan CAHN
AB		10MG		A 071210	001	Mar 11, 1988	Jan CAHN
AB		20MG		A 071211	001	Mar 11, 1988	Jan CAHN

HALOPERIDOL DECANOATE

		INJECTABLE;INJECTION					
		HALOPERIDOL DECANOATE					
	@	TEVA PHARMS USA	EQ 50MG BASE/ML	A 075393	001	May 11, 1999	Jan DISC
	@		EQ 100MG BASE/ML	A 075393	002	May 11, 1999	Jan DISC

HALOPERIDOL LACTATE

		CONCENTRATE;ORAL					
		HALOPERIDOL					
AA	RUBICON	EQ 2MG	BASE/ML	A 218371	001	Jan 31, 2024	Jan NEWA

HYDRALAZINE HYDROCHLORIDE

		INJECTABLE;INJECTION					
		HYDRALAZINE HYDROCHLORIDE					
>A>	AP	ADRASTEIA PHARMA	20MG/ML	A 203110	001	Jun 29, 2015	Feb CAHN
>D>	AP	BEOWULF ASSET	20MG/ML	A 203110	001	Jun 29, 2015	Feb CAHN

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

		TABLET;ORAL					
		ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE					
AB	I3 PHARMS	37.5MG;	20MG	A 215988	001	Jan 17, 2024	Jan NEWA

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION
DILAUDID

>D>	+	FRESENIUS KABI USA	0.2MG/ML	N019034	006	Jan 16, 2020	Feb CFTG
>A>	AP	+	0.2MG/ML	N019034	006	Jan 16, 2020	Feb CFTG
>D>		+	0.5MG/0.5ML	N019034	007	Feb 10, 2017	Feb CFTG
>A>	AP	+	0.5MG/0.5ML	N019034	007	Feb 10, 2017	Feb CFTG
		+	0.5MG/0.5ML	N019034	007	Feb 10, 2017	Jan NEWA

HYDROMORPHONE HYDROCHLORIDE

>A>	AP	HIKMA	0.2MG/ML	A216899	001	Feb 09, 2024	Feb NFTG
>A>	AP		0.5MG/0.5ML	A216899	002	Feb 09, 2024	Feb NFTG
>A>	AP		1MG/ML	A216899	003	Feb 09, 2024	Feb NEWA
>A>	AP		2MG/ML	A216899	004	Feb 09, 2024	Feb NEWA

SOLUTION; ORAL

HYDROMORPHONE HYDROCHLORIDE

@ GENUS 5MG/5ML

A207108 001 Apr 22, 2020 Jan CAHN

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

@ GENUS 2MG

A077471 002 Dec 09, 2009 Jan CAHN

@ 4MG

A077471 003 Dec 09, 2009 Jan CAHN

@ 8MG

A077471 001 Dec 09, 2009 Jan CAHN

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

@ CREEKWOOD PHARMS 200MG

A040150 001 Jan 27, 1996 Jan CAHN

>D> AB RISE PHARMA 200MG

A212902 001 May 14, 2020 Feb CAHN

>A> AB SENORES PHARMS 200MG

A212902 001 May 14, 2020 Feb CAHN

>D> @ TEVA PHARMS 200MG

A040081 001 Sep 30, 1994 Feb CMFD

>A> AB 200MG

A040081 001 Sep 30, 1994 Feb CMFD

HYDROXYUREA

CAPSULE; ORAL

HYDROXYUREA

>A> AB QILU 500MG

A218021 001 Mar 06, 2024 Feb NEWA

IBRUTINIB

TABLET; ORAL

IMBRUVICA

PHARMACYCLICS LLC 420MG

N210563 003 Feb 16, 2018 Jan CHRS

ICOSAPENT ETHYL

CAPSULE; ORAL

ICOSAPENT ETHYL

>A> AB ASCENT PHARMS INC 1GM

A216811 002 Feb 16, 2024 Feb NEWA

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

>D> @ MYLAN LABS LTD 1MG/ML

A200144 001 Oct 11, 2012 Feb CAHN

>A> @ RISING 1MG/ML

A200144 001 Oct 11, 2012 Feb CAHN

ILOPROST

SOLUTION; INTRAVENOUS

AURLUMYN

>A> +! EICOS SCI 100MCG/ML (100MCG/ML)

N217933 001 Feb 13, 2024 Feb NEWA

INDOMETHACIN

SUSPENSION; ORAL

INDOCIN

AB +! ZYLA 25MG/5ML

N018332 001 Oct 10, 1985 Jan CTEC

INDOMETHACIN

AB NOVITIUM PHARMA 25MG/5ML

A217883 001 Jan 12, 2024 Jan NEWA

>D> IOBENGUANE I-131

SOLUTION; INTRAVENOUS

AZEDRA

>D> +! PROGENICS PHARMS INC 15mCi/ML

N209607 001 Jul 30, 2018 Feb DISC

>A> + @ 15mCi/ML

N209607 001 Jul 30, 2018 Feb DISC

ISOSORBIDE MONONITRATE

TABLET;ORAL

MONOKET

AB	+	OMNIVIUM PHARMS	10MG	N020215	002	Jun 30, 1993	Jan CAHN
AB	+	!	20MG	N020215	001	Jun 30, 1993	Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

ISOSORBIDE MONONITRATE

>A>	AB		SHANDONG	30MG	A214115	002	Feb 08, 2024	Feb NEWA
>A>	AB			60MG	A214115	003	Feb 08, 2024	Feb NEWA
>A>	AB		ZYDUS PHARMS	30MG	A218255	001	Feb 15, 2024	Feb NEWA
>A>	AB			60MG	A218255	002	Feb 15, 2024	Feb NEWA
>A>	AB			120MG	A218255	003	Feb 15, 2024	Feb NEWA

ISOTRETINOIN

CAPSULE;ORAL

ISOTRETINOIN

AB2		AUROBINDO PHARMA	10MG	A218194	001	Jan 29, 2024	Jan NEWA
AB2			20MG	A218194	002	Jan 29, 2024	Jan NEWA
AB2			25MG	A218194	003	Jan 29, 2024	Jan NEWA
AB2			30MG	A218194	004	Jan 29, 2024	Jan NEWA
AB2			35MG	A218194	005	Jan 29, 2024	Jan NEWA
AB2			40MG	A218194	006	Jan 29, 2024	Jan NEWA

KETOCONAZOLE

AEROSOL, FOAM;TOPICAL

EXTINA

>D>	AB	+	MYLAN	2%	N021738	001	Jun 12, 2007	Feb DISC
>A>		+	@	2%	N021738	001	Jun 12, 2007	Feb DISC
			KETOCONAZOLE					
>D>	AB		XIROMED	2%	A213601	001	May 21, 2021	Feb CHRS
>A>	AB		!	2%	A213601	001	May 21, 2021	Feb CHRS

TABLET;ORAL

KETOCONAZOLE

>D>	AB		RISE PHARMA	200MG	A075912	001	Jan 10, 2002	Feb CAHN
>A>	AB		SENORES PHARMS	200MG	A075912	001	Jan 10, 2002	Feb CAHN

LACOSAMIDE

SOLUTION;INTRAVENOUS

LACOSAMIDE

>A>	AP		HAINAN POLY	200MG/20ML (10MG/ML)	A217311	001	Feb 13, 2024	Feb NEWA
-----	----	--	-------------	----------------------	---------	-----	--------------	----------

SOLUTION;ORAL

LACOSAMIDE

AA			AUROBINDO PHARMA LTD	10MG/ML	A209224	001	Jan 24, 2024	Jan NEWA
----	--	--	----------------------	---------	---------	-----	--------------	----------

LACTULOSE

SOLUTION;ORAL, RECTAL

LACTULOSE

>D>	AA		PAI HOLDINGS PHARM	10GM/15ML	A074077	001	Jul 03, 1995	Feb DISC
>A>			@	10GM/15ML	A074077	001	Jul 03, 1995	Feb DISC

LAMIVUDINE

TABLET;ORAL

LAMIVUDINE

		@	MYLAN LABS LTD	150MG	A078545	001	Mar 05, 2019	Jan DISC
		@		300MG	A078545	002	Mar 05, 2019	Jan DISC

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

COMBIVIR

		+	@	VIIV HLTHCARE	150MG;300MG	N020857	001	Sep 26, 1997	Jan DISC
--	--	---	---	---------------	-------------	---------	-----	--------------	----------

LAMIVUDINE AND ZIDOVUDINE

AB		!	HETERO LABS LTD III	150MG;300MG	A079124	001	Sep 17, 2015	Jan CHRS
----	--	---	---------------------	-------------	---------	-----	--------------	----------

LAMOTRIGINE

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

>D>	AB		ANCHEN PHARMS	25MG	A201374	001	Dec 26, 2012	Feb DISC
>A>			@	25MG	A201374	001	Dec 26, 2012	Feb DISC
>D>	AB			50MG	A201374	002	Dec 26, 2012	Feb DISC
>A>			@	50MG	A201374	002	Dec 26, 2012	Feb DISC
>D>	AB			100MG	A201374	003	Dec 26, 2012	Feb DISC

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

>A>	@	100MG	A201374	003	Dec 26, 2012	Feb	DISC
>D>	AB	200MG	A201374	004	Dec 26, 2012	Feb	DISC
>A>	@	200MG	A201374	004	Dec 26, 2012	Feb	DISC
>D>	AB	250MG	A201374	005	Dec 26, 2012	Feb	DISC
>A>	@	250MG	A201374	005	Dec 26, 2012	Feb	DISC
>D>	AB	300MG	A201374	006	Dec 26, 2012	Feb	DISC
>A>	@	300MG	A201374	006	Dec 26, 2012	Feb	DISC

LENALIDOMIDE

CAPSULE;ORAL

LENALIDOMIDE

>A>	AB	QILU	2.5MG	A217265	001	Feb 22, 2024	Feb	NEWA
>A>	AB		5MG	A217265	002	Feb 22, 2024	Feb	NEWA
>A>	AB		10MG	A217265	003	Feb 22, 2024	Feb	NEWA
>A>	AB		15MG	A217265	004	Feb 22, 2024	Feb	NEWA
>A>	AB		20MG	A217265	005	Feb 22, 2024	Feb	NEWA
>A>	AB		25MG	A217265	006	Feb 22, 2024	Feb	NEWA

LEVETIRACETAM

INJECTABLE;INTRAVENOUS

LEVETIRACETAM

>A>	AP	ADRASTEIA PHARMA	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Feb	CAHN
>D>	AP	BAXTER HLTHCARE CORP	500MG/100ML (5MG/ML)	A217059	001	Oct 02, 2023	Feb	CTNA
>D>	AP		1GM/100ML (10MG/ML)	A217059	002	Oct 02, 2023	Feb	CTNA
>D>	AP		1.5GM/100ML (15MG/ML)	A217059	003	Oct 02, 2023	Feb	CTNA
>D>	AP	BEOWULF ASSET	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Feb	CAHN
		LEVETIRACETAM IN SODIUM CHLORIDE						
>A>	AP	B BRAUN MEDICAL INC	500MG/100ML (5MG/ML)	A209705	001	Feb 27, 2024	Feb	NEWA
>A>	AP		1GM/100ML (10MG/ML)	A209705	002	Feb 27, 2024	Feb	NEWA
>A>	AP		1.5GM/100ML (15MG/ML)	A209705	003	Feb 27, 2024	Feb	NEWA
>A>	AP	BAXTER HLTHCARE CORP	500MG/100ML (5MG/ML)	A217059	001	Oct 02, 2023	Feb	CTNA
>A>	AP		1GM/100ML (10MG/ML)	A217059	002	Oct 02, 2023	Feb	CTNA
>A>	AP		1.5GM/100ML (15MG/ML)	A217059	003	Oct 02, 2023	Feb	CTNA
>A>	AP	HIKMA	500MG/100ML (5MG/ML)	A211356	001	Feb 12, 2024	Feb	NEWA
>A>	AP		1GM/100ML (10MG/ML)	A211356	002	Feb 12, 2024	Feb	NEWA
>A>	AP		1.5GM/100ML (15MG/ML)	A211356	003	Feb 12, 2024	Feb	NEWA
>D>	+!	HQ SPCLT PHARMA	250MG/50ML (5MG/ML)	N202543	004	Dec 14, 2020	Feb	DISC
>A>	+ @		250MG/50ML (5MG/ML)	N202543	004	Dec 14, 2020	Feb	DISC

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM

>D>	AB	ANCHEN PHARMS	500MG	A091360	001	Oct 04, 2011	Feb	DISC
>A>	@		500MG	A091360	001	Oct 04, 2011	Feb	DISC
>D>	AB		750MG	A091360	002	Oct 04, 2011	Feb	DISC
>A>	@		750MG	A091360	002	Oct 04, 2011	Feb	DISC

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	KNACK	EQ 250MG/50ML (EQ 5MG/ML)	A216164	001	Jan 29, 2024	Jan	NEWA
AP		EQ 500MG/100ML (EQ 5MG/ML)	A216164	002	Jan 29, 2024	Jan	NEWA
AP		EQ 750MG/150ML (EQ 5MG/ML)	A216164	003	Jan 29, 2024	Jan	NEWA

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

LEVOTHYROXINE SODIUM

>D>	AB2	WATSON LABS TEVA	0.025MG	A207588	001	May 10, 2022	Feb	CTEC
>A>	AB1, AB2, AB3, AB4		0.025MG	A207588	001	May 10, 2022	Feb	CTEC
>D>	AB2		0.05MG	A207588	002	May 10, 2022	Feb	CTEC
>A>	AB1, AB2, AB3, AB4		0.05MG	A207588	002	May 10, 2022	Feb	CTEC
>D>	AB2		0.075MG	A207588	003	May 10, 2022	Feb	CTEC
>A>	AB1, AB2, AB3, AB4		0.075MG	A207588	003	May 10, 2022	Feb	CTEC
>D>	AB2		0.088MG	A207588	004	May 10, 2022	Feb	CTEC

TABLET;ORAL

LEVOTHYROXINE SODIUM

>A>	AB1, AB2, AB3, AB4	0.088MG	A207588	004	May 10, 2022	Feb CTEC
>D>	AB2	0.1MG	A207588	005	May 10, 2022	Feb CTEC
>A>	AB1, AB2, AB3, AB4	0.1MG	A207588	005	May 10, 2022	Feb CTEC
>D>	AB2	0.112MG	A207588	006	May 10, 2022	Feb CTEC
>A>	AB1, AB2, AB3, AB4	0.112MG	A207588	006	May 10, 2022	Feb CTEC
>D>	AB2	0.125MG	A207588	007	May 10, 2022	Feb CTEC
>A>	AB1, AB2, AB3, AB4	0.125MG	A207588	007	May 10, 2022	Feb CTEC
>D>	AB2	0.137MG	A207588	008	May 10, 2022	Feb CTEC
>A>	AB1, AB2, AB3, AB4	0.137MG	A207588	008	May 10, 2022	Feb CTEC
>D>	AB2	0.15MG	A207588	009	May 10, 2022	Feb CTEC
>A>	AB1, AB2, AB3, AB4	0.15MG	A207588	009	May 10, 2022	Feb CTEC
>D>	AB2	0.175MG	A207588	010	May 10, 2022	Feb CTEC
>A>	AB1, AB2, AB3, AB4	0.175MG	A207588	010	May 10, 2022	Feb CTEC
>D>	AB2	0.2MG	A207588	011	May 10, 2022	Feb CTEC
>A>	AB1, AB2, AB3, AB4	0.2MG	A207588	011	May 10, 2022	Feb CTEC
>D>	AB2	0.3MG	A207588	012	May 10, 2022	Feb CTEC
>A>	AB1, AB2, AB3, AB4	0.3MG	A207588	012	May 10, 2022	Feb CTEC

LIDOCAINE HYDROCHLORIDE

SOLUTION;ORAL

LIDOCAINE HYDROCHLORIDE VISCOUS

>A>	AT	PAI HOLDINGS PHARM	2%	A218138	001	Feb 20, 2024	Feb NEWA
-----	----	--------------------	----	---------	-----	--------------	----------

LIFITEGRAST

SOLUTION/DROPS;OPHTHALMIC

XIIDRA

AB	+	BAUSCH AND LOMB INC	5%	N208073	001	Jul 11, 2016	Jan CAHN
----	---	---------------------	----	---------	-----	--------------	----------

LIOthyRONINE SODIUM

TABLET;ORAL

LIOthyRONINE SODIUM

>A>	AB	BIOCON PHARMA	EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Feb CAHN
>A>	AB		EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Feb CAHN
>A>	AB		EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Feb CAHN
>D>	AB	CARNEGIE	EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Feb CAHN
	AB		EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Jan NEWA
>D>	AB		EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Feb CAHN
	AB		EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Jan NEWA
>D>	AB		EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Feb CAHN
	AB		EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Jan NEWA

LISDEXAMFETAMINE DIMESYLATE

CAPSULE;ORAL

LISDEXAMFETAMINE DIMESYLATE

>D>	AB	ACTAVIS ELIZABETH	10MG	A202802	001	Aug 25, 2023	Feb DISC
>A>	@		10MG	A202802	001	Aug 25, 2023	Feb DISC
>D>	AB		20MG	A202802	002	Aug 25, 2023	Feb DISC
>A>	@		20MG	A202802	002	Aug 25, 2023	Feb DISC

CAPSULE;ORAL

LISDEXAMFETAMINE DIMESYLATE

>D>	AB		30MG	A202802	003	Aug 25, 2023	Feb	DISC
>A>	@		30MG	A202802	003	Aug 25, 2023	Feb	DISC
>D>	AB		40MG	A202802	004	Aug 25, 2023	Feb	DISC
>A>	@		40MG	A202802	004	Aug 25, 2023	Feb	DISC
>D>	AB		50MG	A202802	005	Aug 25, 2023	Feb	DISC
>A>	@		50MG	A202802	005	Aug 25, 2023	Feb	DISC
>D>	AB		60MG	A202802	006	Aug 25, 2023	Feb	DISC
>A>	@		60MG	A202802	006	Aug 25, 2023	Feb	DISC
>D>	AB		70MG	A202802	007	Aug 25, 2023	Feb	DISC
>A>	@		70MG	A202802	007	Aug 25, 2023	Feb	DISC
AB	HIKMA		10MG	A202827	007	Jan 17, 2024	Jan	NEWA

TABLET, CHEWABLE;ORAL

LISDEXAMFETAMINE DIMESYLATE

AB	MSN		10MG	A218306	001	Feb 02, 2024	Jan	NEWA
AB			20MG	A218306	002	Feb 02, 2024	Jan	NEWA
AB			30MG	A218306	003	Feb 02, 2024	Jan	NEWA
AB			40MG	A218306	004	Feb 02, 2024	Jan	NEWA
AB			50MG	A218306	005	Feb 02, 2024	Jan	NEWA
AB			60MG	A218306	006	Feb 02, 2024	Jan	NEWA
>D>	AB	TEVA PHARMS	10MG	A215415	001	Aug 25, 2023	Feb	DISC
>A>	@		10MG	A215415	001	Aug 25, 2023	Feb	DISC
>D>	AB		20MG	A215415	002	Aug 25, 2023	Feb	DISC
>A>	@		20MG	A215415	002	Aug 25, 2023	Feb	DISC
>D>	AB		30MG	A215415	003	Aug 25, 2023	Feb	DISC
>A>	@		30MG	A215415	003	Aug 25, 2023	Feb	DISC
>D>	AB		40MG	A215415	004	Aug 25, 2023	Feb	DISC
>A>	@		40MG	A215415	004	Aug 25, 2023	Feb	DISC
>D>	AB		50MG	A215415	005	Aug 25, 2023	Feb	DISC
>A>	@		50MG	A215415	005	Aug 25, 2023	Feb	DISC
>D>	AB		60MG	A215415	006	Aug 25, 2023	Feb	DISC
>A>	@		60MG	A215415	006	Aug 25, 2023	Feb	DISC

LITHIUM CITRATE

SYRUP;ORAL

LITHIUM CITRATE

>D>	AA	!	PAI HOLDINGS PHARM	EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986	Feb	DISC
>A>	@			EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986	Feb	DISC
>D>	AA		RUBICON	EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Feb	CHRS
>A>	AA	!		EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Feb	CHRS
>A>	AA		SAPTALIS PHARMS	EQ 300MG CARBONATE/5ML	A217183	001	Feb 29, 2024	Feb	NEWA

LOMITAPIDE MESYLATE

CAPSULE;ORAL

JUXTAPID

+	CHIESI		EQ 5MG BASE	N203858	001	Dec 21, 2012	Jan	CAHN
+			EQ 10MG BASE	N203858	002	Dec 21, 2012	Jan	CAHN
+			EQ 20MG BASE	N203858	003	Dec 21, 2012	Jan	CAHN
+			EQ 30MG BASE	N203858	004	Apr 23, 2015	Jan	CAHN
+	@		EQ 40MG BASE	N203858	005	Apr 23, 2015	Jan	CAHN
+	@		EQ 60MG BASE	N203858	006	Apr 23, 2015	Jan	CAHN

LOMUSTINE

CAPSULE;ORAL

GLEOSTINE

>D>	+	@	CORDEN PHARMA	5MG	N017588	004	Dec 19, 2014	Feb	CAHN
>D>	+			10MG	N017588	001		Feb	CAHN
>D>	+			40MG	N017588	002		Feb	CAHN
>D>	+	!		100MG	N017588	003		Feb	CAHN
>A>	+	@	LATINA PHARMA	5MG	N017588	004	Dec 19, 2014	Feb	CAHN
>A>	+			10MG	N017588	001		Feb	CAHN
>A>	+			40MG	N017588	002		Feb	CAHN
>A>	+	!		100MG	N017588	003		Feb	CAHN

LOPINAVIR; RITONAVIR

TABLET;ORAL

LOPINAVIR AND RITONAVIR

AB	MYLAN LABS LTD		100MG;25MG	A079074	001	Feb 07, 2024	Jan	NEWA
AB			200MG;50MG	A079074	002	Feb 07, 2024	Jan	NEWA

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

>A>	@	AIPING PHARM INC	25MG	A 090544	001	Oct 06, 2010	Feb CAHN
>A>	@		50MG	A 090544	002	Oct 06, 2010	Feb CAHN
>A>	@		100MG	A 090544	003	Oct 06, 2010	Feb CAHN
AB		CHARTWELL RX	25MG	A 077424	001	Oct 06, 2010	Jan CAHN
AB			50MG	A 077424	002	Oct 06, 2010	Jan CAHN
AB			100MG	A 077424	003	Oct 06, 2010	Jan CAHN
>D>	@	UPSHER SMITH LABS	25MG	A 090544	001	Oct 06, 2010	Feb CAHN
>D>	@		50MG	A 090544	002	Oct 06, 2010	Feb CAHN
>D>	@		100MG	A 090544	003	Oct 06, 2010	Feb CAHN

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

>D>	AB	PIRAMAL HLTHCARE UK	20MG	A 212091	001	Dec 28, 2020	Feb CAHN
>D>	AB		40MG	A 212091	002	Dec 28, 2020	Feb CAHN
>D>	AB		60MG	A 212091	003	Dec 28, 2020	Feb CAHN
>D>	AB		80MG	A 212091	004	Dec 28, 2020	Feb CAHN
>D>	AB		120MG	A 212091	005	Dec 28, 2020	Feb CAHN
>A>	AB	SLATE RUN PHARMA	20MG	A 212091	001	Dec 28, 2020	Feb CAHN
>A>	AB		40MG	A 212091	002	Dec 28, 2020	Feb CAHN
>A>	AB		60MG	A 212091	003	Dec 28, 2020	Feb CAHN
>A>	AB		80MG	A 212091	004	Dec 28, 2020	Feb CAHN
>A>	AB		120MG	A 212091	005	Dec 28, 2020	Feb CAHN

MARAVIROC

TABLET;ORAL

SELZENTRY

+	@	VIIV HLTHCARE	25MG	N 022128	003	Nov 04, 2016	Jan DISC
+	@		75MG	N 022128	004	Nov 04, 2016	Jan DISC

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

ANTIVERT

>D>	AA	+	CASPER PHARMA LLC	50MG	N 010721	001	Jan 20, 1982	Feb CHRS
>A>	AA	+	!	50MG	N 010721	001	Jan 20, 1982	Feb CHRS
>D>			MECLIZINE HYDROCHLORIDE	50MG	A 201451	003	Feb 23, 2011	Feb CMFD
>A>	AA	!	@ AMNEAL PHARMS	50MG	A 201451	003	Feb 23, 2011	Feb CMFD

MEDROXYPROGESTERONE ACETATE

INJECTABLE;INJECTION

MEDROXYPROGESTERONE ACETATE

AB		HONG KONG	150MG/ML	A 076553	001	Jul 28, 2004	Jan CAHN
----	--	-----------	----------	----------	-----	--------------	----------

MELOXICAM

TABLET;ORAL

MELOXICAM

AB	!	ZYDUS PHARMS USA	15MG	A 077921	002	Jul 19, 2006	Jan CTEC
	+	@ BOEHRINGER INGELHEIM	7.5MG	N 020938	001	Apr 13, 2000	Jan DISC
	+	@	15MG	N 020938	002	Aug 23, 2000	Jan DISC

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE

AB		XIAMEN LP PHARM CO	21MG	A 213985	004	Feb 06, 2024	Jan NEWA
----	--	--------------------	------	----------	-----	--------------	----------

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

AB		RENATA	5MG	A 209527	001	May 07, 2018	Jan CAHN
AB			10MG	A 209527	002	May 07, 2018	Jan CAHN

MEPERIDINE HYDROCHLORIDE

TABLET;ORAL

MEPERIDINE HYDROCHLORIDE

>D>		EPIC PHARMA LLC	50MG	A 040331	001	May 28, 1999	Feb CTEC
>A>	AA	!	50MG	A 040331	001	May 28, 1999	Feb CTEC
>D>		@ GENUS	50MG	A 040893	001	Jun 24, 2009	Feb CMFD
>A>	AA		50MG	A 040893	001	Jun 24, 2009	Feb CMFD

TABLET;ORAL

MEPERIDINE HYDROCHLORIDE

@	50MG	A 204893	001	Jun 24, 2009	Jan CAHN
@	75MG	A 040893	002	Jun 24, 2009	Jan CAHN
@	100MG	A 040893	003	Jun 24, 2009	Jan CAHN
@	150MG	A 040893	004	Jun 24, 2009	Jan CAHN

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

>D>	AP	DAEWOONG PHARM CO	500MG/VIAL	A 204854	001	Dec 18, 2015	Feb DISC
>A>	@		500MG/VIAL	A 204854	001	Dec 18, 2015	Feb DISC
>D>	AP		1GM/VIAL	A 204854	002	Dec 18, 2015	Feb DISC
>A>	@		1GM/VIAL	A 204854	002	Dec 18, 2015	Feb DISC

MESALAMINE

TABLET, DELAYED RELEASE;ORAL

MESALAMINE

AB		ANNORA PHARMA	1.2GM	A 216334	001	Feb 05, 2024	Jan NEWA
----	--	---------------	-------	----------	-----	--------------	----------

MESNA

INJECTABLE; INTRAVENOUS

MESNA

>D>	@	MYLAN LABS LTD	100MG/ML	A 203364	001	Jul 18, 2014	Feb CAHN
>A>	@	RISING	100MG/ML	A 203364	001	Jul 18, 2014	Feb CAHN

METAPROTERENOL SULFATE

SYRUP;ORAL

METAPROTERENOL SULFATE

!	GENUS		10MG/5ML	A 073632	001	Jul 22, 1992	Jan CAHN
---	-------	--	----------	----------	-----	--------------	----------

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

@	CHARTWELL RX		500MG;EQ 15MG BASE	A 091273	001	Apr 16, 2013	Jan CAHN
@			850MG;EQ 15MG BASE	A 091273	002	Apr 16, 2013	Jan CAHN

METHOCARBAMOL

TABLET;ORAL

METHOCARBAMOL

>D>	AA	ACME LABS	500MG	A 203550	001	Feb 08, 2017	Feb CAHN
>D>	AA		750MG	A 203550	002	Feb 08, 2017	Feb CAHN
>A>	AA	DBL PHARMS	500MG	A 203550	001	Feb 08, 2017	Feb CAHN
>A>	AA		750MG	A 203550	002	Feb 08, 2017	Feb CAHN

METHSCOPOLAMINE BROMIDE

TABLET;ORAL

METHSCOPOLAMINE BROMIDE

AA		AACE PHARMS	2.5MG	A 216786	001	Feb 01, 2024	Jan NEWA
AA			5MG	A 216786	002	Feb 01, 2024	Jan NEWA

>D> METHYLDOPA

>D> TABLET;ORAL

>D> METHYLDOPA

>D>		CHARTWELL RX	250MG	N 018934	001	Jun 29, 1984	Feb DISC
>A>	@		250MG	N 018934	001	Jun 29, 1984	Feb DISC
			250MG	N 018934	001	Jun 29, 1984	Jan CMFD
>D>	!		500MG	N 018934	002	Jun 29, 1984	Feb DISC
>A>	@		500MG	N 018934	002	Jun 29, 1984	Feb DISC
	!		500MG	N 018934	002	Jun 29, 1984	Jan CMFD

METHYLPREDNISOLONE

TABLET;ORAL

METHYLPREDNISOLONE

>D>	AB	PRAXGEN	4MG	A 212262	001	Jun 27, 2019	Feb DISC
>A>	@		4MG	A 212262	001	Jun 27, 2019	Feb DISC

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION
METHYLPREDNISOLONE ACETATE

AB	HONG KONG	40MG/ML	A040557	001	Feb 23, 2005	Jan	CAHN
AB		80MG/ML	A040557	002	Feb 23, 2005	Jan	CAHN
	@ TEVA PHARMS USA	40MG/ML	A040620	001	Oct 27, 2006	Jan	DISC
	@	80MG/ML	A040620	002	Oct 27, 2006	Jan	DISC

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HYDROCHLORIDE

	@ FRESENIUS KABI USA	EQ 5MG BASE/ML	A208878	001	Mar 28, 2017	Jan	DISC
--	----------------------	----------------	---------	-----	--------------	-----	------

MINOCYCLINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
MINOCYCLINE HYDROCHLORIDE

	@ SUN PHARM INDS LTD	EQ 45MG BASE	A091118	001	Sep 25, 2014	Jan	DISC
	@	EQ 65MG BASE	A091118	003	Dec 03, 2019	Jan	DISC
	@	EQ 80MG BASE	A091118	004	Sep 25, 2014	Jan	DISC
	@	EQ 90MG BASE	A091118	005	Sep 25, 2014	Jan	DISC
	@	EQ 105MG BASE	A091118	006	Sep 25, 2014	Jan	DISC
	@	EQ 115MG BASE	A091118	007	Dec 03, 2019	Jan	DISC
	@	EQ 135MG BASE	A091118	008	Sep 25, 2014	Jan	DISC
	@ ZYDUS PHARMS	EQ 45MG BASE	A203553	001	Nov 16, 2017	Jan	DISC
	@	EQ 55MG BASE	A203553	002	Jun 16, 2023	Jan	DISC
	@	EQ 65MG BASE	A203553	003	Jun 16, 2023	Jan	DISC
	@	EQ 80MG BASE	A203553	004	Nov 16, 2017	Jan	DISC
	@	EQ 90MG BASE	A203553	005	Nov 16, 2017	Jan	DISC
	@	EQ 105MG BASE	A203553	006	Nov 16, 2017	Jan	DISC
	@	EQ 115MG BASE	A203553	007	Jun 16, 2023	Jan	DISC
	@	EQ 135MG BASE	A203553	008	Nov 16, 2017	Jan	DISC

MIRABEGRON

TABLET, EXTENDED RELEASE; ORAL
MIRABEGRON

>A>	AB	ALKEM LABS LTD	25MG	A215948	001	Feb 12, 2024	Feb	NEWA
>A>	AB		50MG	A215948	002	Feb 12, 2024	Feb	NEWA

MIRTAZAPINE

TABLET; ORAL
MIRTAZAPINE

>A>	AB	AIPING PHARM INC	15MG	A076219	001	Jun 19, 2003	Feb	CAHN
>A>	AB		30MG	A076219	002	Jun 19, 2003	Feb	CAHN
>A>	AB		45MG	A076219	003	Jun 19, 2003	Feb	CAHN
>D>	AB	UPSHER SMITH LABS	15MG	A076219	001	Jun 19, 2003	Feb	CAHN
>D>	AB		30MG	A076219	002	Jun 19, 2003	Feb	CAHN
>D>	AB		45MG	A076219	003	Jun 19, 2003	Feb	CAHN

MONTELUKAST SODIUM

GRANULE; ORAL
MONTELUKAST SODIUM

	@ TEVA PHARMS	EQ 4MG BASE/PACKET	A090955	001	Aug 03, 2012	Jan	DISC
--	---------------	--------------------	---------	-----	--------------	-----	------

MORPHINE SULFATE

SOLUTION; ORAL
MORPHINE SULFATE

AA	WINDER LABS LLC	10MG/5ML	A211454	001	Feb 12, 2021	Jan	CMFD
AA		20MG/5ML	A211454	002	Feb 12, 2021	Jan	CMFD
AA		100MG/5ML	A211454	003	Feb 12, 2021	Jan	CMFD

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
VIGAMOX

AT1	+!	HARROW EYE	EQ 0.5% BASE	N021598	001	Apr 15, 2003	Jan	CAHN
-----	----	------------	--------------	---------	-----	--------------	-----	------

MYCOPHENOLATE MOFETIL

TABLET; ORAL
MYCOPHENOLATE MOFETIL

>D>	AB	AMNEAL	500MG	A090606	001	Jul 16, 2010	Feb	DISC
>A>		@	500MG	A090606	001	Jul 16, 2010	Feb	DISC
>A>	AB	AUROBINDO PHARMA	500MG	A217937	001	Feb 20, 2024	Feb	NEWA

MYCOPHENOLIC SODIUM

TABLET, DELAYED RELEASE;ORAL
MYCOPHENOLIC SODIUM

>A>	AB	AUROBINDO PHARMA LTD	EQ 180MG BASE	A218603	001	Feb 27, 2024	Feb NEWA
>A>	AB		EQ 360MG BASE	A218603	002	Feb 27, 2024	Feb NEWA

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION
NALOXONE HYDROCHLORIDE

>A>	AP	MANKIND PHARMA	0.4MG/ML	A218404	001	Feb 29, 2024	Feb NEWA
	AP	PAR STERILE PRODUCTS	1MG/ML	A215964	001	Jul 29, 2022	Jan CMFD

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
NALTREXONE

@ TEVA PHARMS USA INC 380MG/VIAL
VIVITROL

A213195 001 Jul 06, 2023 Jan DISC

+! ALKERMES 380MG/VIAL

N021897 001 Apr 13, 2006 Jan CTEC

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

NEBIVOLOL HYDROCHLORIDE

>A>	AB	APOTEX	EQ 10MG BASE	A209741	001	Feb 27, 2024	Feb NEWA
>A>	AB		EQ 20MG BASE	A209741	002	Feb 27, 2024	Feb NEWA

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS
NEOSTIGMINE METHYLSULFATE

AP NIVAGEN PHARMS INC 5MG/10ML (0.5MG/ML)
AP 10MG/10ML (1MG/ML)

A212627 001 Nov 03, 2022 Jan CAHN
A212627 002 Nov 03, 2022 Jan CAHN

NICARDIPINE HYDROCHLORIDE

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

>D>		@ RK PHARMA	25MG/10ML (2.5MG/ML)	A090664	001	Nov 17, 2009	Feb CMFD
>A>	AP		25MG/10ML (2.5MG/ML)	A090664	001	Nov 17, 2009	Feb CMFD

NIRAPARIB TOSYLATE

>D> CAPSULE;ORAL
>D> ZEJULA

>D>		+! GLAXOSMITHKLINE	EQ 100MG BASE	N208447	001	Mar 27, 2017	Feb DISC
>A>		+ @	EQ 100MG BASE	N208447	001	Mar 27, 2017	Feb DISC

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN

>D>	AB	ACTAVIS LABS FL INC	25MG	A091095	001	Jun 18, 2015	Feb DISC
>A>		@	25MG	A091095	001	Jun 18, 2015	Feb DISC
>D>	AB		50MG	A091095	002	Jun 18, 2015	Feb DISC
>A>		@	50MG	A091095	002	Jun 18, 2015	Feb DISC
>D>	AB		100MG	A091095	003	Jun 18, 2015	Feb DISC
>A>		@	100MG	A091095	003	Jun 18, 2015	Feb DISC

NITROGLYCERIN

OINTMENT;INTRA-ANAL
NITROGLYCERIN

>A>	AB	COSETTE	0.4%	A216103	001	Feb 16, 2024	Feb NFTG
>D>		+! ABBVIE	0.4%	N021359	001	Jun 21, 2011	Feb CFTG
>A>	AB	+!	0.4%	N021359	001	Jun 21, 2011	Feb CFTG

NOREPINEPHRINE BITARTRATE

SOLUTION;INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

+!		LONG GROVE PHARMS	EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	N214628	001	Oct 06, 2022	Jan CMFD
+!			EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214628	002	Oct 06, 2022	Jan CMFD
+!			EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214628	003	Oct 06, 2022	Jan CMFD

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL

NORTRIPTYLINE HYDROCHLORIDE

>D>	@	MYLAN	EQ 10MG BASE	A 074234	001	Jul 26, 1993	Feb CAHN
>D>	@		EQ 25MG BASE	A 074234	002	Jul 26, 1993	Feb CAHN
>D>	@		EQ 50MG BASE	A 074234	003	Jul 26, 1993	Feb CAHN
>D>	@		EQ 75MG BASE	A 074234	004	Jul 26, 1993	Feb CAHN
>A>	@	RISING	EQ 10MG BASE	A 074234	001	Jul 26, 1993	Feb CAHN
>A>	@		EQ 25MG BASE	A 074234	002	Jul 26, 1993	Feb CAHN
>A>	@		EQ 50MG BASE	A 074234	003	Jul 26, 1993	Feb CAHN
>A>	@		EQ 75MG BASE	A 074234	004	Jul 26, 1993	Feb CAHN

OCTREOTIDE ACETATE

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

AB		TEVA PHARMS USA INC	EQ 10MG BASE/VIAL	A 210317	001	Dec 05, 2023	Jan CTEC
AB			EQ 20MG BASE/VIAL	A 210317	002	Dec 05, 2023	Jan CTEC
AB			EQ 30MG BASE/VIAL	A 210317	003	Dec 05, 2023	Jan CTEC
		SANDOSTATIN LAR					
AB	+	NOVARTIS	EQ 10MG BASE/VIAL	N 021008	001	Nov 25, 1998	Jan CTEC
AB	+		EQ 20MG BASE/VIAL	N 021008	002	Nov 25, 1998	Jan CTEC
AB	+	!	EQ 30MG BASE/VIAL	N 021008	003	Nov 25, 1998	Jan CTEC

ODEVIXIBAT

CAPSULE;ORAL

BYLVAY

+		IPSEN	0.4MG	N 215498	002	Jul 20, 2021	Jan CAHN
+		!	1.2MG	N 215498	004	Jul 20, 2021	Jan CAHN

CAPSULE, PELLETS;ORAL

BYLVAY

+		IPSEN	0.2MG	N 215498	001	Jul 20, 2021	Jan CAHN
+		!	0.6MG	N 215498	003	Jul 20, 2021	Jan CAHN

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OFLOXACIN

>A>	AT	AMNEAL	0.3%	A 211524	001	Mar 01, 2024	Feb NEWA
-----	----	--------	------	----------	-----	--------------	----------

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

AB		BRECKENRIDGE	5MG	A 206227	001	Jan 25, 2024	Jan NEWA
AB			20MG	A 206227	002	Jan 25, 2024	Jan NEWA
AB			40MG	A 206227	003	Jan 25, 2024	Jan NEWA

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

@		SUN PHARM INDS LTD	4MG	A 078602	001	Feb 24, 2011	Jan DISC
@			8MG	A 078602	002	Feb 24, 2011	Jan DISC

ONDANSETRON HYDROCHLORIDE

SOLUTION;ORAL

ONDANSETRON HYDROCHLORIDE

>D>	AA	PHARM ASSOC	EQ 4MG BASE/5ML	A 078127	001	Jun 25, 2007	Feb DISC
>A>		@	EQ 4MG BASE/5ML	A 078127	001	Jun 25, 2007	Feb DISC

OSPEMIFENE

TABLET;ORAL

OSPEMIFENE

>A>	AB	HETERO LABS LTD V	60MG	A 215574	001	Feb 13, 2024	Feb NFTG		
		OSPHERA							
>D>		+	!	DUCHESNAY	60MG	N 203505	001	Feb 26, 2013	Feb CFTG
>A>	AB		+	!	60MG	N 203505	001	Feb 26, 2013	Feb CFTG

OXALIPLATIN

INJECTABLE;INTRAVENOUS

OXALIPLATIN

AP		KINDOS	50MG/10ML (5MG/ML)	A 217348	001	Jan 11, 2024	Jan NEWA
AP			100MG/20ML (5MG/ML)	A 217348	002	Jan 11, 2024	Jan NEWA

OXAPROZIN

TABLET; ORAL
OXAPROZIN
@ TEVA

600MG

A075849 001 Jul 03, 2002 Jan DISC

OXCARBAZEPINE

SUSPENSION; ORAL
OXCARBAZEPINE

>A> AB CARNEGIE 300MG/5ML
>A> AB MEDLEY PHARMS 300MG/5ML

A218278 001 Mar 01, 2024 Feb NEWA
A217782 001 Feb 14, 2024 Feb NEWA

TABLET; ORAL
OXCARBAZEPINE

>A> AB RUBICON 150MG
>A> AB 300MG
>A> AB 600MG
@ ZYDUS 150MG
@ 300MG
@ 600MG

A207717 001 Mar 05, 2024 Feb NEWA
A207717 002 Mar 05, 2024 Feb NEWA
A207717 003 Mar 05, 2024 Feb NEWA
A211747 001 Jul 03, 2023 Jan DISC
A211747 002 Jul 03, 2023 Jan DISC
A211747 003 Jul 03, 2023 Jan DISC

TABLET, EXTENDED RELEASE; ORAL
OXCARBAZEPINE

>A> AB AJANTA PHARMA LTD 150MG
>A> AB 300MG
>A> AB 600MG

A217659 001 Feb 22, 2024 Feb NEWA
A217659 002 Feb 22, 2024 Feb NEWA
A217659 003 Feb 22, 2024 Feb NEWA

OXTELLAR XR

>D> + SUPERNUS PHARMS 150MG
>A> AB + 150MG
>D> + 300MG
>A> AB + 300MG
>D> +! 600MG
>A> AB +! 600MG

N202810 001 Oct 19, 2012 Feb CTEC
N202810 001 Oct 19, 2012 Feb CTEC
N202810 002 Oct 19, 2012 Feb CTEC
N202810 002 Oct 19, 2012 Feb CTEC
N202810 003 Oct 19, 2012 Feb CTEC
N202810 003 Oct 19, 2012 Feb CTEC

OXYBUTYNIN CHLORIDE

SYRUP; ORAL
OXYBUTYNIN CHLORIDE

>D> AA PHARM ASSOC 5MG/5ML
>A> @ 5MG/5ML

A075137 001 Dec 18, 1998 Feb DISC
A075137 001 Dec 18, 1998 Feb DISC

OZANIMOD HYDROCHLORIDE

CAPSULE; ORAL
ZEPOSIA

+ BRISTOL EQ 0.23MG BASE
+ EQ 0.46MG BASE
+! EQ 0.92MG BASE

N209899 001 Mar 25, 2020 Jan CAHN
N209899 002 Mar 25, 2020 Jan CAHN
N209899 003 Mar 25, 2020 Jan CAHN

PACLITAXEL

POWDER; INTRAVENOUS
ABRAXANE

AB +! BRISTOL-MYERS 100MG/VIAL
AB +! TEVA PHARMS INC 100MG/VIAL

N021660 001 Jan 07, 2005 Jan CTEC
N216338 001 May 11, 2023 Jan CMFD

PALBOCICLIB

TABLET; ORAL
IBRANCE

+ PFIZER 75MG
+ 100MG
+! 125MG

N212436 001 Nov 01, 2019 Jan CTEC
N212436 002 Nov 01, 2019 Jan CTEC
N212436 003 Nov 01, 2019 Jan CTEC

PANTOPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS
PANTOPRAZOLE SODIUM

>D> AP SUN PHARM EQ 40MG BASE/VIAL
>A> @ EQ 40MG BASE/VIAL

A077674 001 Aug 19, 2019 Feb DISC
A077674 001 Aug 19, 2019 Feb DISC

SOLUTION; INTRAVENOUS

>A> PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE
>A> +! BAXTER HLTHCARE CORP EQ 40MG BASE/100ML (EQ 0.4MG
BASE/ML)
>A> +! EQ 40MG BASE/50ML (EQ 0.8MG
BASE/ML)
>A> +! EQ 80MG BASE/100ML (EQ 0.8MG
BASE/ML)

N217512 001 Feb 14, 2024 Feb NEWA
N217512 002 Feb 14, 2024 Feb NEWA
N217512 003 Feb 14, 2024 Feb NEWA

PATIROMER SORBITEX CALCIUM

POWDER; ORAL
VELTASSA

>D>	+	VIFOR PHARMA	EQ 1GM BASE/PACKET	N205739	004	Oct 02, 2023	Feb	DISC
>A>	+	@	EQ 1GM BASE/PACKET	N205739	004	Oct 02, 2023	Feb	DISC

PENICILLIN V POTASSIUM

TABLET; ORAL
PENICILLIN V POTASSIUM

AB	!	AUROBINDO PHARMA	EQ 500MG BASE	A065435	002	Apr 29, 2008	Jan	CHRS
	@	SANDOZ	EQ 250MG BASE	A064071	001	Nov 30, 1995	Jan	DISC
	@		EQ 500MG BASE	A064071	002	Nov 30, 1995	Jan	DISC

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE

AB		ANI PHARMS	400MG	A074878	001	Jul 09, 1997	Jan	CMFD
----	--	------------	-------	---------	-----	--------------	-----	------

PERMETHRIN

CREAM; TOPICAL
PERMETHRIN

	@	DR REDDYS LABS EU	5%	A209732	001	Aug 01, 2023	Jan	DISC
--	---	-------------------	----	---------	-----	--------------	-----	------

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

>D>		ADIPEX-P							
>D>	AA	+	TEVA	37.5MG	A088023	001	Aug 02, 1983	Feb	DISC
>A>		+	@	37.5MG	A088023	001	Aug 02, 1983	Feb	DISC
			PHENTERMINE HYDROCHLORIDE						
>D>	AA		NUVO PHARM	37.5MG	A205017	001	Sep 25, 2014	Feb	CHRS
>A>	AA	!		37.5MG	A205017	001	Sep 25, 2014	Feb	CHRS

PHENTOLAMINE MESYLATE

SOLUTION; OPHTHALMIC
RYZUMVI

	+	FAMYGEN LIFE SCI	EQ 0.75% BASE	N217064	001	Sep 25, 2023	Jan	CAHN
--	---	------------------	---------------	---------	-----	--------------	-----	------

PHENYTOIN

SUSPENSION; ORAL
PHENYTOIN

>D>	AB		PAI HOLDINGS PHARM	125MG/5ML	A040420	001	Apr 19, 2002	Feb	DISC
>A>			@	125MG/5ML	A040420	001	Apr 19, 2002	Feb	DISC

PIMAVANSERIN TARTRATE

CAPSULE; ORAL
NUPLAZID

AB	+	ACADIA PHARMS INC	EQ 34MG BASE	N210793	001	Jun 28, 2018	Jan	CFTG	
			PIMAVANSERIN						
>D>	AB		MSN	EQ 34MG BASE	A214925	001	Jan 16, 2024	Feb	DISC
>A>			@	EQ 34MG BASE	A214925	001	Jan 16, 2024	Feb	DISC
	AB			EQ 34MG BASE	A214925	001	Jan 16, 2024	Jan	NEWA
	AB		ZYDUS	EQ 34MG BASE	A214493	001	Jan 16, 2024	Jan	CAHN
	AB		ZYDUS PHARMS	EQ 34MG BASE	A214493	001	Jan 16, 2024	Jan	NEWA
			TABLET; ORAL						
			NUPLAZID						
AB	+	ACADIA PHARMS INC	EQ 10MG BASE	N207318	002	Jun 28, 2018	Jan	CFTG	
			PIMAVANSERIN						
	AB		ZYDUS	EQ 10MG BASE	A214502	001	Jan 16, 2024	Jan	CAHN
	AB		ZYDUS PHARMS	EQ 10MG BASE	A214502	001	Jan 16, 2024	Jan	NEWA

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

>D>			PIPERACILLIN AND TAZOBACTAM						
>D>	AP		FRESENIUS KABI USA	EQ 12GM BASE/VIAL; EQ 1.5GM BASE/VIAL	A206204	001	May 11, 2018	Feb	DISC
>A>			@	EQ 12GM BASE/VIAL; EQ 1.5GM BASE/VIAL	A206204	001	May 11, 2018	Feb	DISC

POLYMYXIN B SULFATE

INJECTABLE; INJECTION
POLYMYXIN B SULFATE

>A>	AP	ADRASTEA PHARMA	EQ 500,000 UNITS BASE/VIAL	A063000	001	Sep 30, 1994	Feb CAHN
>D>	AP	BEOWULF ASSET	EQ 500,000 UNITS BASE/VIAL	A063000	001	Sep 30, 1994	Feb CAHN

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
POTASSIUM CHLORIDE

>D>	AB	ANCHEN PHARMS	8MEQ	A202886	001	Dec 26, 2013	Feb DISC
>A>		@	8MEQ	A202886	001	Dec 26, 2013	Feb DISC
>D>	AB		10MEQ	A202886	002	Dec 26, 2013	Feb DISC
>A>		@	10MEQ	A202886	002	Dec 26, 2013	Feb DISC

SOLUTION; ORAL
POTASSIUM CHLORIDE

AA		STRIDES PHARMA	20MEQ/15ML	A211665	002	Jan 16, 2024	Jan NEWA
----	--	----------------	------------	---------	-----	--------------	----------

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL
POTASSIUM CITRATE

>D>	AB	TORRENT	5MEQ	A213986	001	Feb 06, 2024	Feb DISC
>A>		@	5MEQ	A213986	001	Feb 06, 2024	Feb DISC
	AB		5MEQ	A213986	001	Feb 06, 2024	Jan NEWA
>D>	AB		10MEQ	A213986	002	Feb 06, 2024	Feb DISC
>A>		@	10MEQ	A213986	002	Feb 06, 2024	Feb DISC
	AB		10MEQ	A213986	002	Feb 06, 2024	Jan NEWA
>D>	AB		15MEQ	A213986	003	Feb 06, 2024	Feb DISC
>A>		@	15MEQ	A213986	003	Feb 06, 2024	Feb DISC
	AB		15MEQ	A213986	003	Feb 06, 2024	Jan NEWA

PRALSETINIB

CAPSULE; ORAL
GAVRETO

>A>	+	BLUEPRINT MEDICINES	100MG	N213721	001	Sep 04, 2020	Feb CAHN
>D>	+	GENENTECH INC	100MG	N213721	001	Sep 04, 2020	Feb CAHN

PREDNISOLONE

SYRUP; ORAL
PREDNISOLONE

>D>	AA	PHARM ASSOC	15MG/5ML	A040399	001	Mar 05, 2003	Feb DISC
>A>		@	15MG/5ML	A040399	001	Mar 05, 2003	Feb DISC

PREDNISON

SOLUTION; ORAL
PREDNISON INTENSOL

+	!	HIKMA	5MG/ML	A088810	001	Feb 20, 1985	Jan CRLD
---	---	-------	--------	---------	-----	--------------	----------

TABLET; ORAL
PREDNISON

>D>	AB	GENEYORK PHARMS	1MG	A211496	001	Dec 28, 2018	Feb DISC
>A>		@	1MG	A211496	001	Dec 28, 2018	Feb DISC
>D>	AB		2.5MG	A210525	004	Dec 07, 2018	Feb DISC
>A>		@	2.5MG	A210525	004	Dec 07, 2018	Feb DISC
>D>	AB		5MG	A210525	005	Dec 07, 2018	Feb DISC
>A>		@	5MG	A210525	005	Dec 07, 2018	Feb DISC
>D>	AB		10MG	A210525	001	Dec 04, 2018	Feb DISC
>A>		@	10MG	A210525	001	Dec 04, 2018	Feb DISC
>D>	AB		20MG	A210525	002	Dec 04, 2018	Feb DISC
>A>		@	20MG	A210525	002	Dec 04, 2018	Feb DISC
>D>	AB		50MG	A210525	003	Dec 04, 2018	Feb DISC
>A>		@	50MG	A210525	003	Dec 04, 2018	Feb DISC

PREGABALIN

CAPSULE; ORAL
PREGABALIN

>D>		@ ACI	25MG	A215755	001	Apr 26, 2023	Feb CMFD
>A>	AB		25MG	A215755	001	Apr 26, 2023	Feb CMFD
>D>		@	50MG	A215755	002	Apr 26, 2023	Feb CMFD
>A>	AB		50MG	A215755	002	Apr 26, 2023	Feb CMFD
>D>		@	75MG	A215755	003	Apr 26, 2023	Feb CMFD
>A>	AB		75MG	A215755	003	Apr 26, 2023	Feb CMFD
>D>		@	100MG	A215755	004	Apr 26, 2023	Feb CMFD

CAPSULE;ORAL
PREGABALIN

>A>	AB		100MG	A215755	004	Apr 26, 2023	Feb	CMFD
>D>	@		150MG	A215755	005	Apr 26, 2023	Feb	CMFD
>A>	AB		150MG	A215755	005	Apr 26, 2023	Feb	CMFD
>D>	@		200MG	A215755	006	Apr 26, 2023	Feb	CMFD
>A>	AB		200MG	A215755	006	Apr 26, 2023	Feb	CMFD
>D>	@		225MG	A215755	007	Apr 26, 2023	Feb	CMFD
>A>	AB		225MG	A215755	007	Apr 26, 2023	Feb	CMFD
>D>	@		300MG	A215755	008	Apr 26, 2023	Feb	CMFD
>A>	AB		300MG	A215755	008	Apr 26, 2023	Feb	CMFD
	@	CADILA PHARMS LTD	25MG	A206452	001	Jul 12, 2023	Jan	DISC
	@		50MG	A206452	002	Jul 12, 2023	Jan	DISC
	@		75MG	A206452	003	Jul 12, 2023	Jan	DISC
	@		100MG	A206452	004	Jul 12, 2023	Jan	DISC
	@		150MG	A206452	005	Jul 12, 2023	Jan	DISC
	@		200MG	A206452	006	Jul 12, 2023	Jan	DISC
	@		225MG	A206452	007	Jul 12, 2023	Jan	DISC
	@		300MG	A206452	008	Jul 12, 2023	Jan	DISC
AB		STRIDES PHARMA	25MG	A209883	001	Jan 24, 2024	Jan	NEWA
AB			50MG	A209883	002	Jan 24, 2024	Jan	NEWA
AB			75MG	A209883	003	Jan 24, 2024	Jan	NEWA
AB			100MG	A209883	004	Jan 24, 2024	Jan	NEWA
AB			150MG	A209883	005	Jan 24, 2024	Jan	NEWA
AB			200MG	A209883	006	Jan 24, 2024	Jan	NEWA
AB			225MG	A209883	007	Jan 24, 2024	Jan	NEWA
AB			300MG	A209883	008	Jan 24, 2024	Jan	NEWA
	@	SUN PHARM	25MG	A091157	001	Nov 29, 2019	Jan	DISC
	@		50MG	A091157	002	Nov 29, 2019	Jan	DISC
	@		75MG	A091157	003	Nov 29, 2019	Jan	DISC
	@		100MG	A091157	004	Nov 29, 2019	Jan	DISC
	@		150MG	A091157	005	Nov 29, 2019	Jan	DISC
	@		200MG	A091157	006	Nov 29, 2019	Jan	DISC
	@		225MG	A091157	007	Nov 29, 2019	Jan	DISC
	@		300MG	A091157	008	Nov 29, 2019	Jan	DISC

PRIMIDONE

SUSPENSION;ORAL
MYSOLINE

+	@	FHTA	250MG/5ML	N010401	001		Jan	CAHN
---	---	------	-----------	---------	-----	--	-----	------

TABLET;ORAL
PRIMIDONE

AB		CARNEGIE	50MG	A218366	001	Jan 23, 2024	Jan	NEWA
AB			250MG	A218366	002	Jan 23, 2024	Jan	NEWA

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
PROPRANOLOL HYDROCHLORIDE

AB		LUPIN LTD	60MG	A204349	001	Jan 12, 2024	Jan	NEWA
AB			80MG	A204349	002	Jan 12, 2024	Jan	NEWA
AB			120MG	A204349	003	Jan 12, 2024	Jan	NEWA
AB			160MG	A204349	004	Jan 12, 2024	Jan	NEWA

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL
PYRIDOSTIGMINE BROMIDE

AB		ANI PHARMS	60MG	A040512	001	Oct 08, 2003	Jan	CMFD
----	--	------------	------	---------	-----	--------------	-----	------

QUETIAPINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL
QUETIAPINE FUMARATE

>D>	AB		EQ 50MG BASE	A090482	001	May 09, 2017	Feb	DISC
>A>	@		EQ 50MG BASE	A090482	001	May 09, 2017	Feb	DISC
>D>	AB		EQ 150MG BASE	A090482	002	May 09, 2017	Feb	DISC
>A>	@		EQ 150MG BASE	A090482	002	May 09, 2017	Feb	DISC
>D>	AB		EQ 200MG BASE	A090482	003	May 09, 2017	Feb	DISC
>A>	@		EQ 200MG BASE	A090482	003	May 09, 2017	Feb	DISC
>D>	AB		EQ 300MG BASE	A090482	004	May 09, 2017	Feb	DISC
>A>	@		EQ 300MG BASE	A090482	004	May 09, 2017	Feb	DISC
>D>	AB		EQ 400MG BASE	A090482	005	May 09, 2017	Feb	DISC
>A>	@		EQ 400MG BASE	A090482	005	May 09, 2017	Feb	DISC

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

>D>	AB	PAR PHARM	EQ 150MG BASE	A075180	001	Jan 28, 1999	Feb DISC
>A>		@	EQ 150MG BASE	A075180	001	Jan 28, 1999	Feb DISC
>D>	AB		EQ 300MG BASE	A075180	002	Jan 28, 1999	Feb DISC
>A>		@	EQ 300MG BASE	A075180	002	Jan 28, 1999	Feb DISC

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL

RANOLAZINE

@ PIRAMAL HLTHCARE UK

500MG

A213085 001 Jul 25, 2023 Jan DISC

@

1GM

A213085 002 Jul 25, 2023 Jan DISC

RISPERIDONE

INJECTABLE; INTRAMUSCULAR

RISPERDAL CONSTA

AB	+	JANSSEN PHARMS	12.5MG/VIAL	N021346	004	Apr 12, 2007	Jan CMS1
AB	+	!	25MG/VIAL	N021346	001	Oct 29, 2003	Jan CMS1
AB	+		37.5MG/VIAL	N021346	002	Oct 29, 2003	Jan CMS1
AB	+		50MG/VIAL	N021346	003	Oct 29, 2003	Jan CMS1

RISPERIDONE

AB		TEVA PHARMS USA INC	12.5MG/VIAL	A214068	001	Dec 05, 2023	Jan CMS1
AB			25MG/VIAL	A214068	002	Dec 05, 2023	Jan CMS1
AB			37.5MG/VIAL	A214068	003	Dec 05, 2023	Jan CMS1
AB			50MG/VIAL	A214068	004	Dec 05, 2023	Jan CMS1

SOLUTION; ORAL

RISPERIDONE

>D>	AA	PHARM ASSOC	1MG/ML	A077719	001	Jul 29, 2009	Feb DISC
>A>		@	1MG/ML	A077719	001	Jul 29, 2009	Feb DISC

TABLET; ORAL

RISPERIDONE

>A>	AB	RENATA	0.25MG	A078707	001	Dec 29, 2008	Feb CAHN
>A>	AB		0.5MG	A078707	002	Dec 29, 2008	Feb CAHN
>A>	AB		1MG	A078707	003	Dec 29, 2008	Feb CAHN
>A>	AB		2MG	A078707	004	Dec 29, 2008	Feb CAHN
>A>	AB		3MG	A078707	005	Dec 29, 2008	Feb CAHN
>A>	AB		4MG	A078707	006	Dec 29, 2008	Feb CAHN
>D>	AB	WESTMINSTER PHARMS	0.25MG	A078707	001	Dec 29, 2008	Feb CAHN
>D>	AB		0.5MG	A078707	002	Dec 29, 2008	Feb CAHN
>D>	AB		1MG	A078707	003	Dec 29, 2008	Feb CAHN
>D>	AB		2MG	A078707	004	Dec 29, 2008	Feb CAHN
>D>	AB		3MG	A078707	005	Dec 29, 2008	Feb CAHN
>D>	AB		4MG	A078707	006	Dec 29, 2008	Feb CAHN

RITONAVIR

CAPSULE; ORAL

RITONAVIR

>A>		MYLAN	100MG	A205024	001	Feb 16, 2024	Feb NEWA
-----	--	-------	-------	---------	-----	--------------	----------

ROSUVASTATIN CALCIUM

TABLET; ORAL

ROSUVASTATIN CALCIUM

@ SANDOZ

EQ 5MG BASE

A079171 001 Jul 19, 2016 Jan DISC

@

EQ 10MG BASE

A079171 002 Jul 19, 2016 Jan DISC

@

EQ 20MG BASE

A079171 003 Jul 19, 2016 Jan DISC

@

EQ 40MG BASE

A079171 004 Jul 19, 2016 Jan DISC

SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL

SAXAGLIPTIN

>D>	AB	AMNEAL	EQ 2.5MG BASE	A205941	001	Jul 31, 2023	Feb DISC
>A>		@	EQ 2.5MG BASE	A205941	001	Jul 31, 2023	Feb DISC
>D>	AB		EQ 5MG BASE	A205941	002	Jul 31, 2023	Feb DISC
>A>		@	EQ 5MG BASE	A205941	002	Jul 31, 2023	Feb DISC

SILVER SULFADIAZINE

CREAM;TOPICAL
SSD

AB	+	DR REDDYS LA	1%	N018578	001	Feb 25, 1982	Jan	CRLD
AB	!		1%	N018578	001	Feb 25, 1982	Jan	CHRS

SODIUM BICARBONATE

INJECTABLE;INJECTION
SODIUM BICARBONATE

>A>	AP	NIVAGEN PHARMS INC	1MEQ/ML	A216042	001	Feb 27, 2024	Feb	NEWA
		@ STERISCIENCE	1MEQ/ML	A217594	001	Jun 28, 2023	Jan	DISC

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS
SODIUM FLUORIDE F-18

AP	!	PETNET	10-200mCi/ML	A203890	001	Sep 28, 2015	Jan	CHRS
		@ SOFIE	10-200mCi/ML	A203544	001	Dec 26, 2012	Jan	DISC

SOLIFENACIN SUCCINATE

TABLET;ORAL
SOLIFENACIN SUCCINATE

>A>	AB	MACLEODS PHARMS LTD	5MG	A204374	001	Feb 20, 2024	Feb	NEWA
>A>	AB		10MG	A204374	002	Feb 20, 2024	Feb	NEWA

SOTALOL HYDROCHLORIDE

TABLET;ORAL
SOTALOL HYDROCHLORIDE

>D>		@ MYLAN	80MG	A075725	001	Dec 19, 2000	Feb	CAHN
>D>		@	120MG	A075725	002	Dec 19, 2000	Feb	CAHN
>D>		@	160MG	A075725	003	Dec 19, 2000	Feb	CAHN
>D>		@	240MG	A075725	004	Dec 19, 2000	Feb	CAHN
>A>		@ RISING	80MG	A075725	001	Dec 19, 2000	Feb	CAHN
>A>		@	120MG	A075725	002	Dec 19, 2000	Feb	CAHN
>A>		@	160MG	A075725	003	Dec 19, 2000	Feb	CAHN
>A>		@	240MG	A075725	004	Dec 19, 2000	Feb	CAHN

STERILE WATER FOR INJECTION

LIQUID;N/A
STERILE WATER FOR INJECTION

>A>	AP	AM REGENT	100% (5ML)	A217341	003	Feb 09, 2024	Feb	NEWA
-----	----	-----------	------------	---------	-----	--------------	-----	------

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION
SUCCINYLCHOLINE CHLORIDE
SOLUTION;INTRAMUSCULAR, INTRAVENOUS
SUCCINYLCHOLINE CHLORIDE

AP		NIVAGEN PHARMS INC	20MG/ML	A211625	001	May 19, 2020	Jan	CAHN
AP		DR REDDYS	100MG/5ML (20MG/ML)	A218467	001	Jan 17, 2024	Jan	NEWA
AP	+	HIKMA	100MG/5ML (20MG/ML)	N215143	001	Aug 20, 2021	Jan	CFTG

SUCRALFATE

SUSPENSION;ORAL
SUCRALFATE

AB		PD PARTNERS	1GM/10ML	A213549	001	Jan 17, 2024	Jan	NEWA
----	--	-------------	----------	---------	-----	--------------	-----	------

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS
IMITREX

+	@	GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N020080	001	Dec 28, 1992	Jan	DISC
AP	!	EUGIA PHARMA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A202758	001	Apr 23, 2013	Jan	CHRS
>D>	AP	PAR PHARM	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077332	001	Oct 09, 2009	Feb	DISC
>A>		@	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077332	001	Oct 09, 2009	Feb	DISC

SUNITINIB MALATE

CAPSULE;ORAL
SUNITINIB MALATE

>D>	AB	NOVUGEN	EQ 12.5MG BASE	A218012	001	Aug 21, 2023	Feb DISC
>A>	@		EQ 12.5MG BASE	A218012	001	Aug 21, 2023	Feb DISC
>D>	AB		EQ 25MG BASE	A218012	002	Aug 21, 2023	Feb DISC
>A>	@		EQ 25MG BASE	A218012	002	Aug 21, 2023	Feb DISC
>D>	AB		EQ 37.5MG BASE	A218012	003	Aug 21, 2023	Feb DISC
>A>	@		EQ 37.5MG BASE	A218012	003	Aug 21, 2023	Feb DISC
>D>	AB		EQ 50MG BASE	A218012	004	Aug 21, 2023	Feb DISC
>A>	@		EQ 50MG BASE	A218012	004	Aug 21, 2023	Feb DISC

TACROLIMUS

CAPSULE, EXTENDED RELEASE;ORAL
ASTAGRAF XL

AB	+	ASTELLAS	EQ 0.5MG BASE	N204096	001	Jul 19, 2013	Jan CFTG
AB	+		EQ 1MG BASE	N204096	002	Jul 19, 2013	Jan CFTG
AB	+	!	EQ 5MG BASE	N204096	003	Jul 19, 2013	Jan CFTG
<u>TACROLIMUS</u>							
AB		CHENGDU	EQ 0.5MG BASE	A215012	001	Jan 25, 2024	Jan NFTG
AB			EQ 1MG BASE	A215012	002	Jan 25, 2024	Jan NFTG
AB			EQ 5MG BASE	A215012	003	Jan 25, 2024	Jan NFTG

TADALAFIL

TABLET;ORAL
TADALAFIL

>A>	AB1	SHANDONG	20MG	A216279	001	Mar 04, 2024	Feb NEWA
-----	-----	----------	------	---------	-----	--------------	----------

TEMAZEPAM

CAPSULE;ORAL
TEMAZEPAM

AB		CHARTWELL RX	15MG	A071427	001	Jan 12, 1988	Jan CAHN
AB			30MG	A071428	001	Jan 12, 1988	Jan CAHN

TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL
TENOFOVIR DISOPROXIL FUMARATE

>A>	AB	MYLAN LABS LTD	300MG	A079071	001	Feb 29, 2024	Feb NEWA
-----	----	----------------	-------	---------	-----	--------------	----------

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL
TERAZOSIN HYDROCHLORIDE

AB		BIONPHARMA	EQ 1MG BASE	A075667	001	Jul 28, 2000	Jan CMFD
AB			EQ 2MG BASE	A075667	002	Jul 28, 2000	Jan CMFD
AB			EQ 5MG BASE	A075667	003	Jul 28, 2000	Jan CMFD
AB			EQ 10MG BASE	A075667	004	Jul 28, 2000	Jan CMFD

TERBINAFINE

GEL;TOPICAL
LAMISIL

>D>	@	HALEON US HOLDINGS	1%	N020846	001	Apr 29, 1998	Feb CAHN
>A>	@	KARO HLTHCARE	1%	N020846	001	Apr 29, 1998	Feb CAHN

TERBINAFINE HYDROCHLORIDE

SOLUTION;TOPICAL
LAMISIL

>D>	@	HALEON US HOLDINGS	1%	N020749	001	Oct 17, 1997	Feb CAHN
>A>	@	KARO HLTHCARE	1%	N020749	001	Oct 17, 1997	Feb CAHN

TESTOSTERONE

GEL, METERED;TRANSDERMAL
FORTESTA

+	@	ENDO PHARMS	10MG/0.5GM ACTUATION	N021463	001	Dec 29, 2010	Jan DISC
<u>TESTOSTERONE</u>							
!		ACTAVIS LABS UT INC	10MG/0.5GM ACTUATION	A204571	001	Aug 05, 2015	Jan CTEC
AB	!		10MG/0.5GM ACTUATION	A204571	001	Aug 05, 2015	Jan CHRS

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
TESTOSTERONE ENANTHATE

>A> AO EUGIA PHARMA 200MG/ML A212659 001 Feb 28, 2024 Feb NEWA

TESTOSTERONE UNDECANOATE

CAPSULE; ORAL
TLANDO

+! VERITY 112.5MG N208088 001 Mar 28, 2022 Jan CAHN

TETRABENAZINE

TABLET; ORAL
TETRABENAZINE

>D> AB PIRAMAL HLTHCARE UK 12.5MG A213316 001 Jan 22, 2020 Feb CAHN
>D> AB 25MG A213316 002 Jan 22, 2020 Feb CAHN
>A> AB SLATE RUN PHARMA 12.5MG A213316 001 Jan 22, 2020 Feb CAHN
>A> AB 25MG A213316 002 Jan 22, 2020 Feb CAHN

TETRACYCLINE HYDROCHLORIDE

TABLET; ORAL
SUMYCIN

STRIDES PHARMA 250MG A061147 001 Jan CMFD
! 500MG A061147 004 Jan CMFD

TIOPRONIN

TABLET, DELAYED RELEASE; ORAL
THIOLA EC

AB + MISSION PHARMACAL 100MG N211843 001 Jun 28, 2019 Jan CFTG
AB TIOPRONIN 100MG A216990 001 Jan 30, 2024 Jan NFTG
AB TORRENT 300MG A216990 002 Jan 30, 2024 Jan NEWA

TIRZEPATIDE

SOLUTION; SUBCUTANEOUS
MOUNJARO

+! ELI LILLY AND CO 2.5MG/0.5ML (2.5MG/0.5ML) N215866 007 Jul 28, 2023 Jan NEWA
+! 5MG/0.5ML (5MG/0.5ML) N215866 008 Jul 28, 2023 Jan NEWA
+! 7.5MG/0.5ML (7.5MG/0.5ML) N215866 009 Jul 28, 2023 Jan NEWA
+! 10MG/0.5ML (10MG/0.5ML) N215866 010 Jul 28, 2023 Jan NEWA
+! 12.5MG/0.5ML (12.5MG/0.5ML) N215866 011 Jul 28, 2023 Jan NEWA
+! 15MG/0.5ML (15MG/0.5ML) N215866 012 Jul 28, 2023 Jan NEWA
MOUNJARO (AUTOINJECTOR)
+! ELI LILLY AND CO 2.5MG/0.5ML (2.5MG/0.5ML) N215866 001 May 13, 2022 Jan CTNA
+! 5MG/0.5ML (5MG/0.5ML) N215866 002 May 13, 2022 Jan CTNA
+! 7.5MG/0.5ML (7.5MG/0.5ML) N215866 003 May 13, 2022 Jan CTNA
+! 10MG/0.5ML (10MG/0.5ML) N215866 004 May 13, 2022 Jan CTNA
+! 12.5MG/0.5ML (12.5MG/0.5ML) N215866 005 May 13, 2022 Jan CTNA
+! 15MG/0.5ML (15MG/0.5ML) N215866 006 May 13, 2022 Jan CTNA

TOPIRAMATE

CAPSULE, EXTENDED RELEASE; ORAL
TOPIRAMATE

>D> AB1 AJANTA PHARMA LTD 25MG A215663 001 Aug 15, 2023 Feb DISC
>A> @ 25MG A215663 001 Aug 15, 2023 Feb DISC
>D> AB1 50MG A215663 002 Aug 15, 2023 Feb DISC
>A> @ 50MG A215663 002 Aug 15, 2023 Feb DISC
>D> AB1 100MG A215663 003 Aug 15, 2023 Feb DISC
>A> @ 100MG A215663 003 Aug 15, 2023 Feb DISC
>D> AB1 200MG A215663 004 Aug 15, 2023 Feb DISC
>A> @ 200MG A215663 004 Aug 15, 2023 Feb DISC

TABLET; ORAL

TOPIRAMATE

>A> @ AIPING PHARM INC 25MG A078499 001 Jan 07, 2010 Feb CAHN
>A> @ 50MG A078499 002 Jan 07, 2010 Feb CAHN
>A> @ 100MG A078499 003 Jan 07, 2010 Feb CAHN
>A> @ 200MG A078499 004 Jan 07, 2010 Feb CAHN
@ SUN PHARM INDS LTD 25MG A076327 001 Mar 27, 2009 Jan DISC
@ 100MG A076327 002 Mar 27, 2009 Jan DISC
@ 200MG A076327 003 Mar 27, 2009 Jan DISC
>D> @ UPSHER SMITH LABS 25MG A078499 001 Jan 07, 2010 Feb CAHN
>D> @ 50MG A078499 002 Jan 07, 2010 Feb CAHN

		TABLET;ORAL							
		TOPIRAMATE							
>D>	@	100MG	A078499	003	Jan 07, 2010	Feb	CAHN		
>D>	@	200MG	A078499	004	Jan 07, 2010	Feb	CAHN		
<u>TRIAMCINOLONE ACETONIDE</u>									
		OINTMENT;TOPICAL							
		TRIAMCINOLONE ACETONIDE							
	@	AUROBINDO PHARMA LTD	0.1%	A211315	001	Mar 18, 2020	Jan	CAHN	
	@		0.5%	A211315	002	Mar 18, 2020	Jan	CAHN	
		SPRAY;TOPICAL							
		TRIAMCINOLONE ACETONIDE							
>D>	AT	AKORN	0.147MG/GM	A207094	001	Dec 07, 2016	Feb	CAHN	
>A>	AT	SAPTALIS PHARMS	0.147MG/GM	A207094	001	Dec 07, 2016	Feb	CAHN	
<u>TRIAZOLAM</u>									
		TABLET;ORAL							
		TRIAZOLAM							
>D>	AB	HIKMA	0.125MG	A074224	001	Jun 01, 1994	Feb	DISC	
>A>	@		0.125MG	A074224	001	Jun 01, 1994	Feb	DISC	
>D>	AB		0.25MG	A074224	002	Jun 01, 1994	Feb	DISC	
>A>	@		0.25MG	A074224	002	Jun 01, 1994	Feb	DISC	
<u>TROSPIUM CHLORIDE</u>									
		TABLET;ORAL							
		TROSPIUM CHLORIDE							
>D>	AB	CHARTWELL RX	20MG	A215781	001	Feb 16, 2022	Feb	CAHN	
>A>	AB	ZAMEER PHARMS	20MG	A215781	001	Feb 16, 2022	Feb	CAHN	
<u>UMECLIDINIUM BROMIDE</u>									
		POWDER;INHALATION							
		INCRUSE ELLIPTA							
	+	GLAXO GRP ENGLAND	EQ 0.0625MG BASE/INH	N205382	001	Apr 30, 2014	Jan	CPOT	
<u>VALPROIC ACID</u>									
		SYRUP;ORAL							
		VALPROIC ACID							
AA		QUAGEN	250MG/5ML	A090517	001	May 28, 2010	Jan	CAHN	
<u>VANCOMYCIN HYDROCHLORIDE</u>									
		CAPSULE;ORAL							
		VANCOMYCIN HYDROCHLORIDE							
>D>	AB	PAI HOLDINGS PHARM	EQ 125MG BASE	A065478	001	Apr 09, 2012	Feb	DISC	
>A>	@		EQ 125MG BASE	A065478	001	Apr 09, 2012	Feb	DISC	
>D>	AB		EQ 250MG BASE	A065478	002	Apr 09, 2012	Feb	DISC	
>A>	@		EQ 250MG BASE	A065478	002	Apr 09, 2012	Feb	DISC	
		INJECTABLE;INJECTION							
		VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER							
>D>	+	BAXTER HLTHCARE	EQ 500MG BASE/100ML	N050671	001	Apr 29, 1993	Feb	CPOT	
>D>	+		EQ 750MG BASE/150ML	N050671	002	Dec 20, 2010	Feb	CPOT	
>D>	+		EQ 1GM BASE/200ML	N050671	003	Mar 01, 1999	Feb	CPOT	
		VANCOMYCIN HYDROCHLORIDE							
>D>	AP	PHARM ASSOC	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Feb	DISC	
>A>	@		EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Feb	DISC	
>D>	AP		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Feb	DISC	
>A>	@		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Feb	DISC	
		SOLUTION;INTRAVENOUS							
		VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER							
>A>	+	BAXTER HLTHCARE	EQ 500MG BASE/100ML (EQ 5MG BASE/ML)	N050671	001	Apr 29, 1993	Feb	CPOT	
>A>	+		EQ 750MG BASE/150ML (EQ 5MG BASE/ML)	N050671	002	Dec 20, 2010	Feb	CPOT	
>A>	+		EQ 1GM BASE/200ML (EQ 5MG BASE/ML)	N050671	003	Mar 01, 1999	Feb	CPOT	
>A>	+		EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	N050671	004	Jan 25, 2024	Feb	NEWA	
>A>	+		EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	N050671	005	Jan 25, 2024	Feb	NEWA	

VARENICLINE TARTRATE

TABLET; ORAL

VARENICLINE TARTRATE

>A>	AB	AVALANCHE PHARM	EQ 0.5MG BASE	A217283	001	Mar 06, 2024	Feb NEWA
>A>	AB		EQ 1MG BASE	A217283	002	Mar 06, 2024	Feb NEWA
>A>	AB	MYLAN	EQ 0.5MG BASE	A202019	001	Feb 28, 2024	Feb NEWA
>A>	AB		EQ 1MG BASE	A202019	002	Feb 28, 2024	Feb NEWA

VASOPRESSIN

SOLUTION; INTRAVENOUS

VASOPRESSIN

>A>	AP	GLAND PHARMA LTD	20UNITS/ML (20UNITS/ML)	A216963	001	Feb 09, 2024	Feb NEWA
-----	----	------------------	-------------------------	---------	-----	--------------	----------

ZOLMITRIPTAN

SPRAY; NASAL

ZOLMITRIPTAN

>D>	AB	PADAGIS ISRAEL	5MG/SPRAY	A212469	002	Sep 30, 2021	Feb CHRS
>A>	AB	!	5MG/SPRAY	A212469	002	Sep 30, 2021	Feb CHRS

ALCAFTADINESOLUTION/DROPS;OPHTHALMIC
ALCAFTADINE

>A>	GLAND PHARMA LTD	0.25%	A209706	001	Mar 01, 2024	Feb NEWA
-----	------------------	-------	---------	-----	--------------	----------

BRIMONIDINE TARTRATESOLUTION/DROPS;OPHTHALMIC
BRIMONIDINE TARTRATE

>A>	DR REDDYS LABS SA	0.025%	A216361	001	Feb 16, 2024	Feb NFTG
-----	-------------------	--------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE

>A> SOLUTION;ORAL

>A> CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

>A>	AMNEAL PHARMS	5MG/5ML	A090765	002	Oct 07, 2009	Feb CDFR
-----	---------------	---------	---------	-----	--------------	----------

>A>	@ APOZEAL PHARMS	5MG/5ML	A090474	002	Mar 30, 2009	Feb CDFR
-----	------------------	---------	---------	-----	--------------	----------

>A>	AUROBINDO PHARMA	5MG/5ML	A090750	002	Feb 02, 2010	Feb CDFR
-----	------------------	---------	---------	-----	--------------	----------

>A>	BAJAJ	5MG/5ML	A091327	001	Oct 17, 2011	Feb CDFR
-----	-------	---------	---------	-----	--------------	----------

>A>	CHARTWELL MOLECULAR	5MG/5ML	A091130	001	Apr 22, 2011	Feb CDFR
-----	---------------------	---------	---------	-----	--------------	----------

>A>	@ CHARTWELL RX	5MG/5ML	A090378	002	May 09, 2008	Feb CDFR
-----	----------------	---------	---------	-----	--------------	----------

>A>	@ CYPRESS PHARM	5MG/5ML	A090300	001	Oct 10, 2008	Feb CDFR
-----	-----------------	---------	---------	-----	--------------	----------

>A>	HETERO LABS LTD III	5MG/5ML	A210622	001	Mar 13, 2019	Feb CDFR
-----	---------------------	---------	---------	-----	--------------	----------

>A>	PERRIGO R AND D	5MG/5ML	A204226	001	Sep 09, 2013	Feb CDFR
-----	-----------------	---------	---------	-----	--------------	----------

>A>		5MG/5ML	A090254	002	Apr 09, 2008	Feb CDFR
-----	--	---------	---------	-----	--------------	----------

>A>	@ PHARM ASSOC	5MG/5ML	A090188	002	Apr 22, 2008	Feb CDFR
-----	---------------	---------	---------	-----	--------------	----------

>A>	QUAGEN	5MG/5ML	A212266	001	May 16, 2019	Feb CDFR
-----	--------	---------	---------	-----	--------------	----------

>A>	@ RANBAXY LABS LTD	5MG/5ML	A090183	002	Apr 24, 2008	Feb CDFR
-----	--------------------	---------	---------	-----	--------------	----------

>A>	TARO	5MG/5ML	A090182	002	Apr 22, 2008	Feb CDFR
-----	------	---------	---------	-----	--------------	----------

>A>		5MG/5ML	A201546	001	May 20, 2011	Feb CDFR
-----	--	---------	---------	-----	--------------	----------

>A>	@ TRIS PHARMA INC	5MG/5ML	A090572	001	Nov 16, 2012	Feb CDFR
-----	-------------------	---------	---------	-----	--------------	----------

>A> CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

>A>	AMNEAL PHARMS	5MG/5ML	A090765	001	Oct 07, 2009	Feb CDFR
-----	---------------	---------	---------	-----	--------------	----------

>A>	@ APOZEAL PHARMS	5MG/5ML	A090474	001	Mar 30, 2009	Feb CDFR
-----	------------------	---------	---------	-----	--------------	----------

>A>	AUROBINDO PHARMA	5MG/5ML	A090750	001	Feb 02, 2010	Feb CDFR
-----	------------------	---------	---------	-----	--------------	----------

>A>	BAJAJ	5MG/5ML	A091327	002	Oct 17, 2011	Feb CDFR
-----	-------	---------	---------	-----	--------------	----------

>A>	CHARTWELL MOLECULAR	5MG/5ML	A091130	002	Apr 22, 2011	Feb CDFR
-----	---------------------	---------	---------	-----	--------------	----------

>A>	@ CHARTWELL RX	5MG/5ML	A090378	001	May 09, 2008	Feb CDFR
-----	----------------	---------	---------	-----	--------------	----------

>A>	@ CYPRESS PHARM	5MG/5ML	A090300	002	Oct 10, 2008	Feb CDFR
-----	-----------------	---------	---------	-----	--------------	----------

>A>	PERRIGO R AND D	5MG/5ML	A090254	001	Apr 09, 2008	Feb CDFR
-----	-----------------	---------	---------	-----	--------------	----------

>A>	@ PHARM ASSOC	5MG/5ML	A090188	001	Apr 22, 2008	Feb CDFR
-----	---------------	---------	---------	-----	--------------	----------

>A>	@ RANBAXY LABS LTD	5MG/5ML	A090183	001	Apr 24, 2008	Feb CDFR
-----	--------------------	---------	---------	-----	--------------	----------

>A>	TARO	5MG/5ML	A090182	001	Apr 22, 2008	Feb CDFR
-----	------	---------	---------	-----	--------------	----------

>A>		5MG/5ML	A201546	002	May 20, 2011	Feb CDFR
-----	--	---------	---------	-----	--------------	----------

>A>	@ TRIS PHARMA INC	5MG/5ML	A090572	002	Nov 16, 2012	Feb CDFR
-----	-------------------	---------	---------	-----	--------------	----------

>A> CHILDREN'S ZYRTEC ALLERGY

>A>	+! J AND J CONSUMER INC	5MG/5ML	N022155	002	Nov 16, 2007	Feb CDFR
-----	-------------------------	---------	---------	-----	--------------	----------

>A> CHILDREN'S ZYRTEC HIVES RELIEF

>A>	+! J AND J CONSUMER INC	5MG/5ML	N022155	001	Nov 16, 2007	Feb CDFR
-----	-------------------------	---------	---------	-----	--------------	----------

>D> SYRUP;ORAL

>D> CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

>D>	AMNEAL PHARMS	5MG/5ML	A090765	002	Oct 07, 2009	Feb CDFR
-----	---------------	---------	---------	-----	--------------	----------

>D>	@ APOZEAL PHARMS	5MG/5ML	A090474	002	Mar 30, 2009	Feb CDFR
-----	------------------	---------	---------	-----	--------------	----------

>D>	AUROBINDO PHARMA	5MG/5ML	A090750	002	Feb 02, 2010	Feb CDFR
-----	------------------	---------	---------	-----	--------------	----------

>D>	BAJAJ	5MG/5ML	A091327	001	Oct 17, 2011	Feb CDFR
-----	-------	---------	---------	-----	--------------	----------

>D>	CHARTWELL MOLECULAR	5MG/5ML	A091130	001	Apr 22, 2011	Feb CDFR
-----	---------------------	---------	---------	-----	--------------	----------

>D>	@ CHARTWELL RX	5MG/5ML	A090378	002	May 09, 2008	Feb CDFR
-----	----------------	---------	---------	-----	--------------	----------

>D>	@ CYPRESS PHARM	5MG/5ML	A090300	001	Oct 10, 2008	Feb CDFR
-----	-----------------	---------	---------	-----	--------------	----------

>D>	HETERO LABS LTD III	5MG/5ML	A210622	001	Mar 13, 2019	Feb CDFR
-----	---------------------	---------	---------	-----	--------------	----------

>D>	PERRIGO R AND D	5MG/5ML	A204226	001	Sep 09, 2013	Feb CDFR
-----	-----------------	---------	---------	-----	--------------	----------

>D>		5MG/5ML	A090254	002	Apr 09, 2008	Feb CDFR
-----	--	---------	---------	-----	--------------	----------

>D>	@ PHARM ASSOC	5MG/5ML	A090188	002	Apr 22, 2008	Feb CDFR
-----	---------------	---------	---------	-----	--------------	----------

>D>	QUAGEN	5MG/5ML	A212266	001	May 16, 2019	Feb CDFR
-----	--------	---------	---------	-----	--------------	----------

>D>	@ RANBAXY LABS LTD	5MG/5ML	A090183	002	Apr 24, 2008	Feb CDFR
-----	--------------------	---------	---------	-----	--------------	----------

>D>	TARO	5MG/5ML	A090182	002	Apr 22, 2008	Feb CDFR
-----	------	---------	---------	-----	--------------	----------

>D>		5MG/5ML	A201546	001	May 20, 2011	Feb CDFR
-----	--	---------	---------	-----	--------------	----------

>D>	@ TRIS PHARMA INC	5MG/5ML	A090572	001	Nov 16, 2012	Feb CDFR
-----	-------------------	---------	---------	-----	--------------	----------

>D> CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

>D>	AMNEAL PHARMS	5MG/5ML	A090765	001	Oct 07, 2009	Feb CDFR
-----	---------------	---------	---------	-----	--------------	----------

>D>	@ APOZEAL PHARMS	5MG/5ML	A090474	001	Mar 30, 2009	Feb CDFR
-----	------------------	---------	---------	-----	--------------	----------

>D>	AUROBINDO PHARMA	5MG/5ML	A090750	001	Feb 02, 2010	Feb CDFR
-----	------------------	---------	---------	-----	--------------	----------

>D>	BAJAJ	5MG/5ML	A091327	002	Oct 17, 2011	Feb CDFR
-----	-------	---------	---------	-----	--------------	----------

>D>	CHARTWELL MOLECULAR	5MG/5ML	A091130	002	Apr 22, 2011	Feb CDFR
-----	---------------------	---------	---------	-----	--------------	----------

>D>	SYRUP;ORAL								
>D>	CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF								
>D>	@ CHARTWELL RX	5MG/5ML	A090378	001	May 09, 2008	Feb	CDFR		
>D>	@ CYPRESS PHARM	5MG/5ML	A090300	002	Oct 10, 2008	Feb	CDFR		
>D>	PERRIGO R AND D	5MG/5ML	A090254	001	Apr 09, 2008	Feb	CDFR		
>D>	@ PHARM ASSOC	5MG/5ML	A090188	001	Apr 22, 2008	Feb	CDFR		
>D>	@ RANBAXY LABS LTD	5MG/5ML	A090183	001	Apr 24, 2008	Feb	CDFR		
>D>	TARO	5MG/5ML	A090182	001	Apr 22, 2008	Feb	CDFR		
>D>		5MG/5ML	A201546	002	May 20, 2011	Feb	CDFR		
>D>	@ TRIS PHARMA INC	5MG/5ML	A090572	002	Nov 16, 2012	Feb	CDFR		
>D>	CHILDREN'S ZYRTEC ALLERGY								
>D>	+! J AND J CONSUMER INC	5MG/5ML	N022155	002	Nov 16, 2007	Feb	CDFR		
>D>	CHILDREN'S ZYRTEC HIVES RELIEF								
>D>	+! J AND J CONSUMER INC	5MG/5ML	N022155	001	Nov 16, 2007	Feb	CDFR		
	<u>DOCOSANOL</u>								
	CREAM;TOPICAL								
	DOCOSANOL								
>A>	AUROBINDO PHARMA LTD	10%	A217090	001	Mar 01, 2024	Feb	NEWA		
	<u>ESOMEPRAZOLE MAGNESIUM</u>								
	CAPSULE, DELAYED RELEASE;ORAL								
	ESOMEPRAZOLE MAGNESIUM								
>D>	ANDA REPOSITORY	EQ 20MG BASE	A216149	001	Mar 15, 2023	Feb	CAHN		
>A>	GUARDIAN DRUG	EQ 20MG BASE	A216149	001	Mar 15, 2023	Feb	CAHN		
	TABLET, DELAYED RELEASE;ORAL								
	ESOMEPRAZOLE MAGNESIUM								
	@ AUROBINDO PHARMA LTD	EQ 20MG BASE	A214473	001	Jul 12, 2023	Jan	DISC		
	<u>IBUPROFEN</u>								
	CAPSULE;ORAL								
	IBUPROFEN								
>A>	PATHEON SOFTGELS	EQ 200MG FREE ACID AND POTASSIUM SALT	A217236	001	Feb 13, 2024	Feb	NEWA		
	<u>LOPERAMIDE HYDROCHLORIDE</u>								
	SOLUTION;ORAL								
	LOPERAMIDE HYDROCHLORIDE								
	@ SAPTALIS PHARMS	1MG/5ML	A074352	001	Nov 17, 1995	Jan	CAHN		
	<u>NAPROXEN SODIUM</u>								
	TABLET;ORAL								
	NAPROXEN SODIUM								
	@ SUN PHARM INDS LTD	220MG	A091183	001	May 20, 2011	Jan	DISC		
	<u>NICOTINE POLACRILEX</u>								
	TROCHE/LOZENGE;ORAL								
	NICORETTE								
	+ HALEON US HOLDINGS	EQ 2MG BASE	N022360	001	May 18, 2009	Jan	CAHN		
	+!	EQ 4MG BASE	N022360	002	May 18, 2009	Jan	CAHN		
	<u>NORGESTREL</u>								
	TABLET;ORAL								
	OPILL								
>D>	+ @ LABORATOIRE HRA	0.075MG	N017031	001		Feb	CMFD		
>A>	+!	0.075MG	N017031	001		Feb	CMFD		
	<u>OLOPATADINE HYDROCHLORIDE</u>								
	SOLUTION/DROPS;OPHTHALMIC								
	OLOPATADINE HYDROCHLORIDE								
	@ SAPTALIS PHARMS	EQ 0.2% BASE	A204723	001	Dec 05, 2017	Jan	CAHN		
	<u>POVIDONE-IODINE</u>								
>D>	SPONGE;TOPICAL								
>D>	E-Z SCRUB 201								
>D>	+! BECTON DICKINSON	20%	N019240	001	Nov 29, 1985	Feb	DISC		
>A>	+ @	20%	N019240	001	Nov 29, 1985	Feb	DISC		
>D>	E-Z SCRUB 241								
>D>	+! BECTON DICKINSON	10%	N019476	001	Jan 07, 1987	Feb	DISC		
>A>	+ @	10%	N019476	001	Jan 07, 1987	Feb	DISC		

TERBINAFINEGEL;TOPICAL
LAMISIL AT

>D>	+!	HALEON US HOLDINGS	1%	N021958	001	Jul 24, 2006	Feb CAHN
>A>	+!	KARO HLTHCARE	1%	N021958	001	Jul 24, 2006	Feb CAHN

TERBINAFINE HYDROCHLORIDECREAM;TOPICAL
LAMISIL

>D>	+!	HALEON US HOLDINGS	1%	N020980	001	Mar 09, 1999	Feb CAHN
>A>	+!	KARO HLTHCARE	1%	N020980	001	Mar 09, 1999	Feb CAHN

SOLUTION;TOPICAL
LAMISIL AT

>D>	+!	HALEON US HOLDINGS	1%	N021124	001	Mar 17, 2000	Feb CAHN
>A>	+!	KARO HLTHCARE	1%	N021124	001	Mar 17, 2000	Feb CAHN

SPRAY;TOPICAL
LAMISIL AT

>D>	+!	HALEON US HOLDINGS	1%	N021124	002	Mar 17, 2000	Feb CAHN
>A>	+!	KARO HLTHCARE	1%	N021124	002	Mar 17, 2000	Feb CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 2 FEBRUARY 2024

NO FEBRUARY 2024 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO FEBRUARY 2024 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACYCLOVIR - ACYCLOVIR</u>						
A 212361	001				CGT	Jun 12, 2024
<u>ALPELISIB - PIORAY</u>						
N 212526	001 >A>	8227462	Apr 29, 2033	DS DP U-3809		
<u>ALPELISIB - PIORAY</u>						
N 212526	002 >A>	8227462	Apr 29, 2033	DS DP U-3809		
<u>ALPELISIB - PIORAY</u>						
N 212526	003 >A>	8227462	Apr 29, 2033	DS DP U-3809		
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410	001 >A>	11890261	Feb 15, 2038	U-2497		
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410	002 >A>	11890261	Feb 15, 2038	U-2497		
<u>AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN - TALICIA</u>						
N 213004	001 >A>	11878011	May 27, 2042	U-3816		
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905	001 >A>	11896562	Mar 10, 2037	U-3299		
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905	002 >A>	11896562	Mar 10, 2037	U-3299		
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905	003 >A>	11896562	Mar 10, 2037	U-3299		
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905	004 >A>	11896562	Mar 10, 2037	U-3299		
<u>APREPITANT - APONVIE</u>						
N 216457	001	11878074	Sep 18, 2035	U-3787		
<u>AVATROMBOPAG MALEATE - DOPTELET</u>						
N 210238	001	7638536	Jul 28, 2027	DS DP		
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494	001 >A>	7112592	Jan 07, 2026	DS DP U-2244		
	>A>	7112592	Jan 07, 2026	DS DP U-2508		
	>A>	7112592	Jan 07, 2026	DS DP U-282		
	>A>	7112592	Jan 07, 2026	DS DP U-3818		
<u>BACLOFEN - LYVISPAH</u>						
N 215422	001	11850225	Sep 29, 2041	DP U-3488		
		11850225	Sep 29, 2041	DP U-3489		
<u>BACLOFEN - LYVISPAH</u>						
N 215422	002	11850225	Sep 29, 2041	DP U-3488		
		11850225	Sep 29, 2041	DP U-3489		
<u>BACLOFEN - LYVISPAH</u>						
N 215422	003	11850225	Sep 29, 2041	DP U-3488		
		11850225	Sep 29, 2041	DP U-3489		
<u>BARICITINIB - OLUMIANT</u>						
N 207924	001 >A>	8158616	May 31, 2032	DS DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BARICITINIB - OLUMIANT</u>						
N 207924 002	>A> 8158616	May 31, 2032	DS DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 003	>A> 8158616	May 31, 2032	DS DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER</u>						
N 207921 001	11865247	Jan 26, 2038	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER</u>						
N 207921 002	11865247	Jan 26, 2038	DP			
<u>BELZUTIFAN - WELIREG</u>						
N 215383 001				>A> I-931		Dec 14, 2026
<u>BENDAMUSTINE HYDROCHLORIDE - BELRAPZO</u>						
N 205580 001	11872214	Jan 28, 2031	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	11872214	Jan 28, 2031	DP			
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	11865100	Feb 19, 2040	U-3357			
	>A> 11877997	Feb 19, 2040	U-3356			
<u>BERDAZIMER SODIUM - ZELSUVMI</u>						
N 217424 001	>A> 10258564	Nov 22, 2034	U-3797		NCE	Jan 05, 2029
	>A> 10258564	Nov 22, 2034	U-3798			
	>A> 10258564	Nov 22, 2034	U-3799			
	10265334	Jul 03, 2032	DP			
	>A> 10322081	Jul 10, 2035	U-3793			
	>A> 10322081	Jul 10, 2035	U-3794			
	>A> 10322081	Jul 10, 2035	U-3795			
	>A> 10322081	Jul 10, 2035	U-3796			
	10376538	Aug 20, 2030	DP			
	>A> 10736839	Jul 10, 2035	U-3790			
	>A> 10736839	Jul 10, 2035	U-3791			
	>A> 10736839	Jul 10, 2035	U-3792			
	>A> 11040006	Jul 10, 2035	DP U-3789			
	11285098	Feb 28, 2034	DP			
	>A> 11723858	Jul 10, 2035	DP U-3788			
	8282967	May 30, 2026	DS			
	8956658	May 30, 2026	DS			
	>A> 9289442	Jul 03, 2032	DP U-3803			
	9526738	Sep 03, 2031	DP			
	>A> 9737561	Aug 20, 2030	U-3802			
	>A> 9855211	Feb 27, 2034	DP U-3800			
	>A> 9855211	Feb 27, 2034	DP U-3801			
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001	>A> 7777050	Mar 13, 2025	DS DP			
<u>BIRCH TRITERPENES - FILSUVUZ</u>						
N 215064 001	>A> 11083733	Jan 04, 2039	DP		ODE-460	Dec 18, 2030
	>A> 11266660	Jan 04, 2039	U-3811			
	>A> 8828444	Jun 21, 2025	DP			
	>A> 9352041	Nov 24, 2030	U-3811			
	>A> 9827214	Nov 24, 2030	U-3811			
<u>BIVALIRUDIN - ANGIOMAX RTU</u>						
N 211215 001	>A> 11903993	May 20, 2039	U-3817			
	>A> 11918622	May 20, 2039	U-3817			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BROMFENAC SODIUM - BROMFENAC SODIUM</u>						
A 206027	001				PC	Jul 06, 2024
<u>BUDESONIDE - EOHILIA</u>						
N 213976	001	>A> 10293052	Nov 22, 2028	DP	>A> NP	Feb 09, 2027
		>A> 11197822	Nov 09, 2026	DP		
		>A> 11260064	Jan 10, 2039	DP		
		>A> 11357859	Nov 12, 2028	U-3820		
		>A> 11413296	Nov 09, 2026	DP		
		>A> 11564934	Jan 10, 2039	U-3820		
		>A> 8324192	Aug 03, 2029	U-3820		
		>A> 8497258	Nov 09, 2026	U-3820		
		>A> 8679545	Nov 09, 2026	DP		
		>A> 8975243	Nov 09, 2026	U-3820		
		>A> 9050368	Aug 01, 2029	DP		
		>A> 9119863	Nov 09, 2026	U-3820		
<u>BUDESONIDE - TARPEYO</u>						
N 215935	001	>A> 11896719	Jan 23, 2043	U-3810		
		8491932	May 07, 2029	DP U-3269		
		8491932	May 07, 2029	DP U-3781		
<u>BUPIVACAINE - EXPAREL</u>						
N 022496	001				I-929	Nov 09, 2026
<u>BUPIVACAINE - EXPAREL</u>						
N 022496	002				I-929	Nov 09, 2026
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430	001	>A> 11883373	Jan 23, 2043	U-3419		
		>A> 11896563	Dec 01, 2041	U-3419		
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010	001	>A> 11154509	Apr 25, 2028	U-3815		
		>A> 9498486	Apr 25, 2028	U-3814		
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365	001	11865102	Apr 26, 2039	DS DP U-2781		
		11865102	Apr 26, 2039	DS DP U-3236		
		11865102	Apr 26, 2039	DS DP U-3277		
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790	002	8629111	Aug 27, 2024	DP	Y	
		8633162	Aug 27, 2024	U-1479	Y	
		8642556	Aug 27, 2024	DP	Y	
		8648048	Aug 27, 2024	U-1483	Y	
		8685930	Aug 27, 2024	DP	Y	
		9248191	Aug 27, 2024	U-1479	Y	
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806	001				>A> I-908	Mar 16, 2026
					>A> ODE-428	Mar 16, 2030
					>A> PED	Sep 16, 2026
					>A> PED	Sep 16, 2030
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806	002				>A> I-908	Mar 16, 2026
					>A> ODE-428	Mar 16, 2030
					>A> PED	Sep 16, 2026
					>A> PED	Sep 16, 2030
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 217514	001	>A> 11504333	Jun 29, 2038	DP	>A> NP	Mar 16, 2026
		>A> 11504333*PED	Dec 29, 2038		>A> ODE-428	Mar 16, 2030
		>A> 7994185	Jan 20, 2030	DS DP	>A> PED	Sep 16, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 217514 001	>A> 7994185*PED	Jul 20, 2030			>A> PED	Sep 16, 2030
	>A> 8415345	Jan 20, 2030	DS DP			
	>A> 8415345*PED	Jul 20, 2030				
	>A> 8703781	Oct 15, 2030	DS DP U-3565			
	>A> 8703781*PED	Apr 15, 2031				
	>A> 8835443	Jun 10, 2025	U-3565			
	>A> 8835443*PED	Dec 10, 2025				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 001	11890272	Jul 17, 2040	U-3756			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 002	11890272	Jul 17, 2040	U-3756			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	>A> 8168209	Nov 22, 2025	DP	Y		
	>A> 8168209*PED	May 22, 2026				
	>A> 8173708	Nov 22, 2025	U-1641	Y		
	>A> 8173708*PED	May 22, 2026				
	>A> 8283379	Nov 22, 2025	U-1641	Y		
	>A> 8283379*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	>A> 8168209	Nov 22, 2025	DP	Y		
	>A> 8168209*PED	May 22, 2026				
	>A> 8173708	Nov 22, 2025	U-1641	Y		
	>A> 8173708*PED	May 22, 2026				
	>A> 8283379	Nov 22, 2025	U-1641	Y		
	>A> 8283379*PED	May 22, 2026				
	>A> 8329752	Nov 22, 2025	DP	Y		
	>A> 8329752*PED	May 22, 2026				
	>A> 8362085	Nov 22, 2025	U-1641	Y		
	>A> 8362085*PED	May 22, 2026				
	>A> 8598233	Nov 22, 2025	DP	Y		
	>A> 8598233*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 004	>A> 8168209	Nov 22, 2025	DP	Y		
	>A> 8168209*PED	May 22, 2026				
	>A> 8173708	Nov 22, 2025	U-1641	Y		
	>A> 8173708*PED	May 22, 2026				
	>A> 8283379	Nov 22, 2025	U-1641	Y		
	>A> 8283379*PED	May 22, 2026				
	>A> 8329752	Nov 22, 2025	DP	Y		
	>A> 8329752*PED	May 22, 2026				
	>A> 8362085	Nov 22, 2025	U-1641	Y		
	>A> 8362085*PED	May 22, 2026				
	>A> 8598233	Nov 22, 2025	DP	Y		
	>A> 8598233*PED	May 22, 2026				
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001					M-14	Oct 18, 2026
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002					M-14	Oct 18, 2026
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003					M-14	Oct 18, 2026
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	>A> 11872218	Jan 03, 2028	U-1969			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EFLORNITHINE HYDROCHLORIDE - IWILFIN</u>						
N 215500 001					>A> ODE-462	Dec 13, 2030
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 001	7419983	Jul 06, 2029	DS DP U-2360			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 002	7419983	Jul 06, 2029	DS DP U-2360			
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	7419983	Jul 06, 2029	DS DP			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 002					ODE-457	Jan 07, 2029
<u>EPLONTERSEN SODIUM - WAINUA (AUTOINJECTOR)</u>						
N 217388 001	10683499	Aug 25, 2034	DS DP U-2378		NCE	Dec 21, 2028
	8101743	Apr 01, 2025	DS DP		ODE-461	Dec 21, 2030
	9127276	May 01, 2034	DS			
	9181549	May 01, 2034	DS			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	>A> 10898482	Feb 09, 2036	DP U-2518		>A> I-930	Jan 19, 2027
	>A> 10898482	Feb 09, 2036	DP U-3065			
	>A> 10898482	Feb 09, 2036	DP U-3066			
	>A> 10898482	Feb 09, 2036	DP U-3067			
	>A> 10898482	Feb 09, 2036	DP U-3805			
	>A> 10898482	Feb 09, 2036	DP U-3806			
	>A> 10898482	Feb 09, 2036	DP U-3807			
	>A> 11077106	Feb 02, 2038	U-3196			
	>A> 11077106	Feb 02, 2038	U-3808			
	>A> 11684620	Feb 09, 2036	U-3805			
	>A> 11684620	Feb 09, 2036	U-3806			
	>A> 11684620	Feb 09, 2036	U-3807			
	>A> 9464071	Apr 28, 2031	U-3805			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	>A> 10898482	Feb 09, 2036	DP U-2518		>A> I-930	Jan 19, 2027
	>A> 10898482	Feb 09, 2036	DP U-3065			
	>A> 10898482	Feb 09, 2036	DP U-3066			
	>A> 10898482	Feb 09, 2036	DP U-3067			
	>A> 10898482	Feb 09, 2036	DP U-3805			
	>A> 10898482	Feb 09, 2036	DP U-3806			
	>A> 10898482	Feb 09, 2036	DP U-3807			
	>A> 11077106	Feb 02, 2038	U-3196			
	>A> 11077106	Feb 02, 2038	U-3808			
	>A> 11684620	Feb 09, 2036	U-3805			
	>A> 11684620	Feb 09, 2036	U-3806			
	>A> 11684620	Feb 09, 2036	U-3807			
	>A> 9464071	Apr 28, 2031	U-3805			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	>A> 10898482	Feb 09, 2036	DP U-2518		>A> I-930	Jan 19, 2027
	>A> 10898482	Feb 09, 2036	DP U-3065			
	>A> 10898482	Feb 09, 2036	DP U-3066			
	>A> 10898482	Feb 09, 2036	DP U-3067			
	>A> 10898482	Feb 09, 2036	DP U-3805			
	>A> 10898482	Feb 09, 2036	DP U-3806			
	>A> 10898482	Feb 09, 2036	DP U-3807			
	>A> 11077106	Feb 02, 2038	U-3196			
	>A> 11077106	Feb 02, 2038	U-3808			
	>A> 11684620	Feb 09, 2036	U-3805			
	>A> 11684620	Feb 09, 2036	U-3806			
	>A> 11684620	Feb 09, 2036	U-3807			
	>A> 9464071	Apr 28, 2031	U-3805			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	>A> 11883526	Feb 18, 2040	U-3812			
	>A> 11883526	Feb 18, 2040	U-3813			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	11865179	Nov 21, 2032	DS DP			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 002	11865179	Nov 21, 2032	DS DP			
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001	11850251	Jun 21, 2039	U-3785			
<u>ETRASIMOD ARGININE - VELSIPTIY</u>						
N 216956 001	>A> 11884626	Jun 21, 2036	U-3731			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7612109	Feb 05, 2025	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	7612109	Feb 05, 2025	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	7612109	Feb 05, 2025	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	7612109	Feb 05, 2025	DS DP			
<u>FIDAXOMICIN - DIFICID</u>						
N 213138 001	8586551*PED	Jan 15, 2024				
<u>FINERENONE - KERENDIA</u>						
N 215341 001	>A> RE49826	Jul 29, 2035	DS			
<u>FINERENONE - KERENDIA</u>						
N 215341 002	>A> RE49826	Jul 29, 2035	DS			
<u>FLUOROMETHOLONE - FLUOROMETHOLONE</u>						
A 216348 001					CGT	Jul 07, 2024
<u>FRUQUINTINIB - FRUZAOLA</u>						
N 217564 001				>A>	NCE	Nov 30, 2028
<u>FRUQUINTINIB - FRUZAOLA</u>						
N 217564 002				>A>	NCE	Nov 30, 2028
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	8404215	Mar 09, 2032	U-1383	Y		
<u>HALOBETASOL PROPIONATE - HALOBETASOL PROPIONATE</u>						
A 215266 001					PC	Jun 24, 2024
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520 001					NCE GAIN	Nov 15, 2028 Nov 15, 2033
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520 002					NCE GAIN	Nov 15, 2028 Nov 15, 2033

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8754090	Jun 03, 2031	U-1456	Y		
	8754090*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	8754090	Jun 03, 2031	U-1456	Y		
	8754090*PED	Dec 03, 2031				
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 001					>A> NPP	May 11, 2026
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002					>A> NPP	May 11, 2026
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 003					>A> NPP	May 11, 2026
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	11850245	Apr 30, 2030	U-1455			
	11850245	Apr 30, 2030	U-172			
<u>INDOMETHACIN - INDOMETHACIN</u>						
A 217883 001					CGT	Jul 10, 2024
<u>IPTACOPAN HYDROCHLORIDE - FABHALTA</u>						
N 218276 001					NCE ODE-456	Dec 05, 2028 Dec 05, 2030
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 001					NPP >A> ODE-454 >A> ODE-458 PED >A> PED >A> PED	Dec 08, 2026 Dec 08, 2030 Dec 08, 2030 Jun 08, 2027 Jun 08, 2031 Jun 08, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 002					NPP >A> ODE-454 >A> ODE-458 PED >A> PED >A> PED	Dec 08, 2026 Dec 08, 2030 Dec 08, 2030 Jun 08, 2027 Jun 08, 2031 Jun 08, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501 001					NPP >A> ODE-453 ODE-459 PED PED >A> PED	Dec 08, 2026 Dec 08, 2030 Dec 08, 2030 Jun 08, 2027 Jun 08, 2031 Jun 08, 2031
<u>LATANOPROST - IYUZEH</u>						
N 216472 001	>A> 8637054	Jul 08, 2031	DP U-446			
<u>LETTERMOVIR - PREVYMIS</u>						
N 209939 001	>A> RE46791	Jan 18, 2029	DS DP			
<u>LETTERMOVIR - PREVYMIS</u>						
N 209939 002	>A> RE46791	Jan 18, 2029	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 001	>A> RE46791	Jan 18, 2029	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 002	>A> RE46791	Jan 18, 2029	DS DP			
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	>A> 11850182	Sep 14, 2029	DP U-3819			
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	>A> 11850182	Sep 14, 2029	DP U-3819			
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	>A> 11850182	Sep 14, 2029	DP U-3819			
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	11872318	May 03, 2033	DP			
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933 001	11872318	May 03, 2033	DP			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	8598119	Dec 28, 2029	U-543	Y		
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 001					>A> M-303	Jan 08, 2027
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 002					>A> M-303	Jan 08, 2027
<u>MIFEPRISTONE - MIFEPRISTONE</u>						
A 211436 001					PC	Jul 17, 2024
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	>A> 11903938	Aug 17, 2038	DS U-2371			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 001	11878049	Jul 31, 2041	U-3782			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 002	11878049	Jul 31, 2041	U-3782			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 003	11878049	Jul 31, 2041	U-3782			
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	>A> 11903918	Feb 27, 2035	U-1384			
<u>NALOXONE HYDROCHLORIDE - RIVIVE</u>						
N 217722 001	11806428	May 11, 2032	DP			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 001	11872211	May 19, 2043	U-3754		NCE	Nov 27, 2028
	11884634	Aug 09, 2039	DP		ODE-452	Nov 27, 2030
	11884635	Aug 09, 2039	DP			
	>A> 11905255	Aug 09, 2039	DP			
<u>NITROGLYCERIN - NITROGLYCERIN</u>						
A 216103 001					>A> CGT	Aug 21, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232 001	11857595	Feb 03, 2036	U-3784			
	>A> 11890316	Dec 28, 2040	U-3232			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	>A> 7449464	Sep 08, 2027	DS DP			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	>A> 7449464	Sep 08, 2027	DS DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	>A> 11896599	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	>A> 11896599	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	>A> 11896599	Apr 13, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200534 001					M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200535 001					M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200535 002					M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 201194 001					M-14	Jul 21, 2024
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001	11844841	Dec 09, 2038	DP U-3172			
	11844841	Dec 09, 2038	DP U-3173			
	11844841	Dec 09, 2038	DP U-3174			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	11857646	Mar 16, 2037	U-665			
<u>PERFLUTREN - DEFINITY RT</u>						
N 021064 002	11857646	Mar 16, 2037	U-665			
<u>PHENTOLAMINE MESYLATE - RYZUMVI</u>						
N 217064 001	10278918	Jan 31, 2034	DP			
	10772829	Jan 31, 2034	DP			
	11090261	Jan 31, 2034	DP			
	>A> 11400077	Oct 25, 2039	U-3804			
	11844858	Jan 31, 2034	DP			
	9795560	Jan 31, 2034	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE - MYDCOMBI</u>						
N 215352 001	11839487	Jul 15, 2031	U-3685			
<u>PIFLUFOLASTAT F-18 - PYLARIFY</u>						
N 214793 001	11851407	Jun 09, 2037	DS DP U-3130			
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 001					ODE-451	Dec 01, 2030
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 002					ODE-451	Dec 01, 2030

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001	11872192	Apr 03, 2039	U-2952			
<u>REMDESIVIR - VEKLURY</u>						
N 214787 001	10065958	Sep 16, 2031	DS		D-183	Jan 21, 2025
	10065958*PED	Mar 16, 2032			M-301	Jul 13, 2026
	10675296	Jul 10, 2038	DP		NCE	Oct 22, 2025
	10675296*PED	Jan 10, 2039			NPP	Apr 25, 2025
	10695361	Sep 16, 2036	U-2984		PED	Jul 21, 2025
	10695361	Sep 16, 2036	U-3249		PED	Oct 25, 2025
	10695361	Sep 16, 2036	U-3367		PED	Apr 22, 2026
	10695361	Sep 16, 2036	U-3368		PED	Jan 13, 2027
	10695361*PED	Mar 16, 2037				
	11007208	Sep 16, 2036	U-2984			
	11007208	Sep 16, 2036	U-3249			
	11007208	Sep 16, 2036	U-3367			
	11007208	Sep 16, 2036	U-3368			
	11007208*PED	Mar 16, 2037				
	11266681	Jul 10, 2038	U-2984			
	11266681	Jul 10, 2038	U-3249			
	11266681	Jul 10, 2038	U-3367			
	11266681	Jul 10, 2038	U-3368			
	11266681*PED	Jan 10, 2039				
	11382926	Sep 16, 2036	U-3367			
	11382926	Sep 16, 2036	U-3368			
	11382926*PED	Mar 16, 2037				
	11491169	May 28, 2041	U-3484			
	11491169	May 28, 2041	U-3485			
	11491169*PED	Nov 28, 2041				
	11492353	Dec 08, 2031	DS			
	11492353*PED	Jun 08, 2032				
	8008264	Sep 06, 2029	DS DP			
	8008264*PED	Mar 06, 2030				
	8318682	Apr 22, 2029	DS DP			
	8318682*PED	Oct 22, 2029				
	9724360	Oct 29, 2035	DS DP			
	9724360*PED	Apr 29, 2036				
	9949994	Oct 29, 2035	DS			
	9949994*PED	Apr 29, 2036				
	RE46762	Apr 22, 2029	DS DP			
	RE46762*PED	Oct 22, 2029				
<u>REMDESIVIR - VEKLURY</u>						
N 214787 002	10065958	Sep 16, 2031	DS		D-183	Jan 21, 2025
	10065958*PED	Mar 16, 2032			M-301	Jul 13, 2026
	10675296	Jul 10, 2038	DP		NCE	Oct 22, 2025
	10675296*PED	Jan 10, 2039			NPP	Apr 25, 2025
	10695361	Sep 16, 2036	U-2984		PED	Jul 21, 2025
	10695361	Sep 16, 2036	U-3249		PED	Oct 25, 2025
	10695361	Sep 16, 2036	U-3367		PED	Apr 22, 2026
	10695361	Sep 16, 2036	U-3368		PED	Jan 13, 2027
	10695361*PED	Mar 16, 2037				
	11007208	Sep 16, 2036	U-2984			
	11007208	Sep 16, 2036	U-3249			
	11007208	Sep 16, 2036	U-3367			
	11007208	Sep 16, 2036	U-3368			
	11007208*PED	Mar 16, 2037				
	11266681	Jul 10, 2038	U-2984			
	11266681	Jul 10, 2038	U-3249			
	11266681	Jul 10, 2038	U-3367			
	11266681	Jul 10, 2038	U-3368			
	11266681*PED	Jan 10, 2039				
	11382926	Sep 16, 2036	U-3367			
	11382926	Sep 16, 2036	U-3368			
	11382926*PED	Mar 16, 2037				
	11491169	May 28, 2041	U-3484			
	11491169	May 28, 2041	U-3485			
	11491169*PED	Nov 28, 2041				
	11492353	Dec 08, 2031	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>REMDESIVIR - VEKLURY</u>						
N 214787 002	11492353*PED	Jun 08, 2032				
	8008264	Sep 06, 2029	DS DP			
	8008264*PED	Mar 06, 2030				
	8318682	Apr 22, 2029	DS DP			
	8318682*PED	Oct 22, 2029				
	9724360	Oct 29, 2035	DS DP			
	9724360*PED	Apr 29, 2036				
	9949994	Oct 29, 2035	DS			
	9949994*PED	Apr 29, 2036				
	RE46762	Apr 22, 2029	DS DP			
	RE46762*PED	Oct 22, 2029				
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 001					ODE-455	Nov 15, 2030
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	7125879	Apr 21, 2025	DS DP U-1153			
	7125879	Apr 21, 2025	DS DP U-1307			
	7125879	Apr 21, 2025	DS DP U-1740			
	7125879	Apr 21, 2025	DS DP U-3353			
	7125879*PED	Oct 21, 2025				
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	>A> 11896585	Dec 30, 2040	DP			
	>A> 11903933	Dec 30, 2040	DP			
<u>ROFLUMILAST - ZORYVE</u>						
N 217242 001					NP	Dec 15, 2026
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 001	7425637	Mar 13, 2025	DS			
	8178693	Mar 13, 2025	DS DP			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 002	7425637	Mar 13, 2025	DS			
	8178693	Mar 13, 2025	DS DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 001	>A> 11896572	Jul 21, 2037	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 002	>A> 11896572	Jul 21, 2037	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 003	>A> 11896572	Jul 21, 2037	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 004	>A> 11896572	Jul 21, 2037	DP			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	11857528	Mar 19, 2040	U-3521			
	>A> 11865098	Jun 01, 2038	U-2548			
	11872203	Dec 30, 2042	U-3693			
	11872204	Dec 30, 2042	U-3693			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	11857528	Mar 19, 2040	U-3521			
	>A> 11865098	Jun 01, 2038	U-2548			
	11872203	Dec 30, 2042	U-3693			
	11872204	Dec 30, 2042	U-3693			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	10155002	Sep 12, 2031	U-2736			
	10420775	Sep 12, 2031	U-2736			
	10420775	Sep 12, 2031	U-2852			
	10420775	Sep 12, 2031	U-2853			
	11052093	Apr 13, 2032	DS DP U-2736			
	11052093	Apr 13, 2032	DS DP U-2852			
	11052093	Apr 13, 2032	DS DP U-2853			
	11491163	Apr 11, 2033	U-2736			
	11491163	Apr 11, 2033	U-2852			
	11491163	Apr 11, 2033	U-2853			
	8765732	Sep 12, 2031	U-2852			
	8765732	Sep 12, 2031	U-2853			
	9090562	Sep 12, 2031	DS DP			
	9549931	Sep 12, 2031	U-2736			
	9549931	Sep 12, 2031	U-2852			
	9549931	Sep 12, 2031	U-2853			
	9855275	Sep 12, 2031	U-2736			
<u>TECOVIRIMAT - TPOXX</u>						
N 208627 001	>A> 11890270	Aug 08, 2032	U-2346			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 001	11844804	Jun 04, 2033	U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	11844804	Jun 04, 2033	U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	11844804	Jun 04, 2033	U-2418			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 007	>A> 11357820	Jun 14, 2039	DS DP		>A> NCE	May 13, 2027
	>A> 9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 008	>A> 11357820	Jun 14, 2039	DS DP		>A> NCE	May 13, 2027
	>A> 9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 009	>A> 11357820	Jun 14, 2039	DS DP		>A> NCE	May 13, 2027
	>A> 9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 010	>A> 11357820	Jun 14, 2039	DS DP		>A> NCE	May 13, 2027
	>A> 9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 011	>A> 11357820	Jun 14, 2039	DS DP		>A> NCE	May 13, 2027
	>A> 9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 012	>A> 11357820	Jun 14, 2039	DS DP		>A> NCE	May 13, 2027
	>A> 9474780	Jan 05, 2036	DS DP U-3378			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	7166722	Nov 16, 2024	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	7166722	Nov 16, 2024	DS DP			
<u>TRAVOPROST - IDOSE TR</u>						
N 218010 001					NP	Dec 13, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	11207324	Apr 27, 2038	U-3783			
	11666572	Apr 27, 2038	U-3783			
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	11207324	Apr 27, 2038	U-3783			
	11666572	Apr 27, 2038	U-3783			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 001	11857542	Dec 22, 2041	U-3786			
<u>VAMOROLONE - AGAMREE</u>						
N 215239 001	11690853	Mar 07, 2033	U-3747			
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	11851437	Aug 15, 2037	DS DP			
	>A> 11884674	Aug 15, 2037	U-1745			
	>A> 11884674	Aug 15, 2037	U-2145			
	>A> 11884674	Aug 15, 2037	U-2537			
	>A> 11884674	Aug 15, 2037	U-2666			
	>A> 11884674	Aug 15, 2037	U-3063			
	>A> 11884674	Aug 15, 2037	U-3486			
	>A> 11911386	Jan 19, 2043	U-3715			
	>A> 11911386	Jan 19, 2043	U-3716			
	>A> 11911386	Jan 19, 2043	U-3717			
	>A> 11911386	Jan 19, 2043	U-3718			
	>A> 11911386	Jan 19, 2043	U-3719			
	>A> 11911386	Jan 19, 2043	U-3720			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 001	>A> 11884696	Dec 24, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 002	>A> 11884696	Dec 24, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 003	>A> 11884696	Dec 24, 2037	U-2552			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 44TH Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm